Trusted sources developing apps

Article Type
Changed
Display Headline
Trusted sources developing apps

Every month sees new apps launched by established medical organizations. Although these apps don’t have data to confirm their usefulness, at least they come from known and trusted sources. Here’s a roundup of some of the latest. You decide whether or not they’re worth a try.

The Centers for Disease Control and Prevention (CDC) makes it easier for clinicians to find recommended immunization schedules for adults and children through its free CDC Vaccine Schedules app. Look up contraindications to vaccination or catch-up schedules for children and adolescents, or search recommendations for adults based on the presence of diabetes, HIV, pregnancy, or other conditions, among other features.

Courtesy CDC/Douglas Jordan, M.A.
Immunization schedules and more for adults and children can be had through the CDC Vaccine Schedules app.

The free Spot a Stroke FAST app from the American Heart Association and American Stroke Association can help patients and family members identify the signs and symptoms of stroke in order to get timely help. Named after the mnemonic FAST (Face, Arm, Speech, Time), the app includes the ability to phone 911, with a time stamp showing when the call was made, features that may help clinicians in management decisions.

The American College of Cardiology’s free Guideline Clinical App includes three recently updated practice guidelines in its first iteration, on the management of heart failure, assessment of cardiovascular risk, and the treatment of blood cholesterol.

Clinical pearls for emergency medicine developed by the University of Maryland are available in the university’s free app UMEM Pearls.

The U.S. Substance Abuse and Mental Health Services Administration’s free KnowBullying app guides parents and educators on how to start easy, meaningful conversations with children about preventing or responding to bullying. Parents and caregivers who spend at least 15 minutes a day talking with a child can help build a strong relationship that can help prevent bullying, the group says.

The CDC’s free Heads Up app can help parents and caregivers spot the signs and symptoms of a concussion and learn what to do if you think a child or adolescent may have a concussion or other serious brain injury. Bonus: It also offers information on picking the right helmet for specific activities.

While we’re on the topic of pediatrics – the American Academy of Pediatrics (AAP) offers a slew of apps for physicians and parents. One of the most recent is the free AAP Journals app, which received an overall positive but mixed review on iMedicalApps.com.

Residents in the states of Washington or Minnesota can use Planned Parenthood’s free Planned Parenthood Care app in a pilot program that lets them connect with clinicians via video to get birth control methods sent through the mail – contraceptive pills, patches, or rings. The video visit costs $45.

Women who are pregnant or nursing and want to eat fish may like the free Fish4Health app from Purdue University that provides information on the benefits and safety of various fish species and helps them track their intake of healthy fats and mercury.

The European Society of Human Reproduction and Embryology offers its members a free app and/or web-based guidelines on the “Management of Women with Endometriosis.” The app summarizes the 83 recommendations in the guidelines and offers a decision-aid on six key issues in endometriosis.

Among a bevy of apps from the American Red Cross, the recent free Blood Donor app streamlines the process of donating blood, offers rewards to donors from participating retailers, and includes social media features that help promote giving blood.

Is there a new app that you think we should highlight? Let us know.

[email protected]

On Twitter @sherryboschert

References

Author and Disclosure Information

Publications
Legacy Keywords
app, CDC, vaccination, immunization, stroke, cardiology, bullying, concussion, contraception, endometriosis, blood
Sections
Author and Disclosure Information

Author and Disclosure Information

Every month sees new apps launched by established medical organizations. Although these apps don’t have data to confirm their usefulness, at least they come from known and trusted sources. Here’s a roundup of some of the latest. You decide whether or not they’re worth a try.

The Centers for Disease Control and Prevention (CDC) makes it easier for clinicians to find recommended immunization schedules for adults and children through its free CDC Vaccine Schedules app. Look up contraindications to vaccination or catch-up schedules for children and adolescents, or search recommendations for adults based on the presence of diabetes, HIV, pregnancy, or other conditions, among other features.

Courtesy CDC/Douglas Jordan, M.A.
Immunization schedules and more for adults and children can be had through the CDC Vaccine Schedules app.

The free Spot a Stroke FAST app from the American Heart Association and American Stroke Association can help patients and family members identify the signs and symptoms of stroke in order to get timely help. Named after the mnemonic FAST (Face, Arm, Speech, Time), the app includes the ability to phone 911, with a time stamp showing when the call was made, features that may help clinicians in management decisions.

The American College of Cardiology’s free Guideline Clinical App includes three recently updated practice guidelines in its first iteration, on the management of heart failure, assessment of cardiovascular risk, and the treatment of blood cholesterol.

Clinical pearls for emergency medicine developed by the University of Maryland are available in the university’s free app UMEM Pearls.

The U.S. Substance Abuse and Mental Health Services Administration’s free KnowBullying app guides parents and educators on how to start easy, meaningful conversations with children about preventing or responding to bullying. Parents and caregivers who spend at least 15 minutes a day talking with a child can help build a strong relationship that can help prevent bullying, the group says.

The CDC’s free Heads Up app can help parents and caregivers spot the signs and symptoms of a concussion and learn what to do if you think a child or adolescent may have a concussion or other serious brain injury. Bonus: It also offers information on picking the right helmet for specific activities.

While we’re on the topic of pediatrics – the American Academy of Pediatrics (AAP) offers a slew of apps for physicians and parents. One of the most recent is the free AAP Journals app, which received an overall positive but mixed review on iMedicalApps.com.

Residents in the states of Washington or Minnesota can use Planned Parenthood’s free Planned Parenthood Care app in a pilot program that lets them connect with clinicians via video to get birth control methods sent through the mail – contraceptive pills, patches, or rings. The video visit costs $45.

Women who are pregnant or nursing and want to eat fish may like the free Fish4Health app from Purdue University that provides information on the benefits and safety of various fish species and helps them track their intake of healthy fats and mercury.

The European Society of Human Reproduction and Embryology offers its members a free app and/or web-based guidelines on the “Management of Women with Endometriosis.” The app summarizes the 83 recommendations in the guidelines and offers a decision-aid on six key issues in endometriosis.

Among a bevy of apps from the American Red Cross, the recent free Blood Donor app streamlines the process of donating blood, offers rewards to donors from participating retailers, and includes social media features that help promote giving blood.

Is there a new app that you think we should highlight? Let us know.

[email protected]

On Twitter @sherryboschert

Every month sees new apps launched by established medical organizations. Although these apps don’t have data to confirm their usefulness, at least they come from known and trusted sources. Here’s a roundup of some of the latest. You decide whether or not they’re worth a try.

The Centers for Disease Control and Prevention (CDC) makes it easier for clinicians to find recommended immunization schedules for adults and children through its free CDC Vaccine Schedules app. Look up contraindications to vaccination or catch-up schedules for children and adolescents, or search recommendations for adults based on the presence of diabetes, HIV, pregnancy, or other conditions, among other features.

Courtesy CDC/Douglas Jordan, M.A.
Immunization schedules and more for adults and children can be had through the CDC Vaccine Schedules app.

The free Spot a Stroke FAST app from the American Heart Association and American Stroke Association can help patients and family members identify the signs and symptoms of stroke in order to get timely help. Named after the mnemonic FAST (Face, Arm, Speech, Time), the app includes the ability to phone 911, with a time stamp showing when the call was made, features that may help clinicians in management decisions.

The American College of Cardiology’s free Guideline Clinical App includes three recently updated practice guidelines in its first iteration, on the management of heart failure, assessment of cardiovascular risk, and the treatment of blood cholesterol.

Clinical pearls for emergency medicine developed by the University of Maryland are available in the university’s free app UMEM Pearls.

The U.S. Substance Abuse and Mental Health Services Administration’s free KnowBullying app guides parents and educators on how to start easy, meaningful conversations with children about preventing or responding to bullying. Parents and caregivers who spend at least 15 minutes a day talking with a child can help build a strong relationship that can help prevent bullying, the group says.

The CDC’s free Heads Up app can help parents and caregivers spot the signs and symptoms of a concussion and learn what to do if you think a child or adolescent may have a concussion or other serious brain injury. Bonus: It also offers information on picking the right helmet for specific activities.

While we’re on the topic of pediatrics – the American Academy of Pediatrics (AAP) offers a slew of apps for physicians and parents. One of the most recent is the free AAP Journals app, which received an overall positive but mixed review on iMedicalApps.com.

Residents in the states of Washington or Minnesota can use Planned Parenthood’s free Planned Parenthood Care app in a pilot program that lets them connect with clinicians via video to get birth control methods sent through the mail – contraceptive pills, patches, or rings. The video visit costs $45.

Women who are pregnant or nursing and want to eat fish may like the free Fish4Health app from Purdue University that provides information on the benefits and safety of various fish species and helps them track their intake of healthy fats and mercury.

The European Society of Human Reproduction and Embryology offers its members a free app and/or web-based guidelines on the “Management of Women with Endometriosis.” The app summarizes the 83 recommendations in the guidelines and offers a decision-aid on six key issues in endometriosis.

Among a bevy of apps from the American Red Cross, the recent free Blood Donor app streamlines the process of donating blood, offers rewards to donors from participating retailers, and includes social media features that help promote giving blood.

Is there a new app that you think we should highlight? Let us know.

[email protected]

On Twitter @sherryboschert

References

References

Publications
Publications
Article Type
Display Headline
Trusted sources developing apps
Display Headline
Trusted sources developing apps
Legacy Keywords
app, CDC, vaccination, immunization, stroke, cardiology, bullying, concussion, contraception, endometriosis, blood
Legacy Keywords
app, CDC, vaccination, immunization, stroke, cardiology, bullying, concussion, contraception, endometriosis, blood
Sections
Article Source

PURLs Copyright

Inside the Article

COMMENTARY: STARRS’ call for more intensive follow-up valuable

Article Type
Changed
Display Headline
COMMENTARY: STARRS’ call for more intensive follow-up valuable

I would like to provide some perspective on the recent article on the Army STARRS study.

The article, “Predicting Suicides After Psychiatric Hospitalization in U.S. Army Soldiers: The Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)” (JAMA Psychiatry 2014 Nov. 12 [doi: 10.1001/jamapsychiatry.2014.1754]), is one of a series from this multicenter, multiyear study.

Dr. Elspeth Cameron Ritchie

My observations focus on four areas: 1) the history behind this research effort, 2) what we learn from the results, 3) how can we change the way we treat service members based on the results? and 4) the change in accession standards.

This research effort was launched after the rate of suicides continued to rise. Then vice chief of staff, Lt. Gen. Peter Chiarelli was frustrated. He developed a contract with the National Institute of Mental Health to fund an ambitious research agenda that included examining all known suicides to find a way to reduce them.

At that time, I was the chief psychiatrist for the Army and was frankly cynical about the STARRS research. We already knew the risk factors for suicide: previous psychiatric or criminal history, relationship difficulties, problems at work, substance abuse, and access to firearms. But, being a good Army Soldier, I saluted and worked to make it happen. After all, maybe the research would bring some clinically useful revelations.

Lt. Gen. Chiarelli also wanted quick results, within a year. Fat chance, I would have muttered under my breath, had I not been a good Soldier.

So, what does the research tell us, 5 years after the inception? Frankly not much that a military psychiatrist does not already know about the risk factors for suicide in military members. However, the article in JAMA Psychiatry does quantify those risk factors mentioned above.

It also stresses the high risk for those recently psychiatrically hospitalized. Civilian as well as military psychiatrists already know that high-risk patients are the ones who get hospitalized. A caveat: Only 12% of Army suicides were post hospitalization.

However, for a military servicemember, the hospitalization may add to their stress, as it often contributes to an exit from the military. Exit may mean a loss of job, housing, health care, and identity.

What is the actionable intelligence from the article? By actionable intelligence, a military term, I mean here what can clinicians do differently as a result of the research? Do you hospitalize less? Probably not.

The authors suggest more posthospitalization interventions but are guarded in their recommendations. More intensive follow-up could lead to more stigmatization and contribute to an accelerated exit from the military.

Nevertheless, that recommendation is where the value of this article lies. The military system is highly stressed with many competing priorities. Many posts, but not all, have posthospitalization easy access to care. As the article recommends, and I concur, there should be more intensive follow-up. This can be done in many ways, including group settings; military members often prefer groups, as then they can help one another.

There is another subtext to the whole suicide discussion: In the early years of the wars in Iraq and Afghanistan, when the Army was desperate for recruits, it relaxed its accession standards. More came in with prior psychiatric diagnoses. Later, the standards were tightened again; those soldiers were disqualified.

The changes in accession standards often happen in times of conflict. It is not surprising that increases in behavioral health difficulties happen when recruiters are strapped for new recruits and take in marginal performers. Now that the military is drawing down, and it is harder to get into the military with a bad background, suicides in the active duty may taper, irrespective of all the research and suicide prevention programs.

So the article cements what we already knew: People with previous psychiatric problems are more likely to suicide. The question is what can we do about it?

Dr. Ritchie is former chief of psychiatry for the U.S. Army and the current chief clinical officer in the department of behavioral health for the District of Columbia.

References

Author and Disclosure Information

Publications
Legacy Keywords
Army suicides, STARRS, psychiatric hospitalization
Sections
Author and Disclosure Information

Author and Disclosure Information

I would like to provide some perspective on the recent article on the Army STARRS study.

The article, “Predicting Suicides After Psychiatric Hospitalization in U.S. Army Soldiers: The Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)” (JAMA Psychiatry 2014 Nov. 12 [doi: 10.1001/jamapsychiatry.2014.1754]), is one of a series from this multicenter, multiyear study.

Dr. Elspeth Cameron Ritchie

My observations focus on four areas: 1) the history behind this research effort, 2) what we learn from the results, 3) how can we change the way we treat service members based on the results? and 4) the change in accession standards.

This research effort was launched after the rate of suicides continued to rise. Then vice chief of staff, Lt. Gen. Peter Chiarelli was frustrated. He developed a contract with the National Institute of Mental Health to fund an ambitious research agenda that included examining all known suicides to find a way to reduce them.

At that time, I was the chief psychiatrist for the Army and was frankly cynical about the STARRS research. We already knew the risk factors for suicide: previous psychiatric or criminal history, relationship difficulties, problems at work, substance abuse, and access to firearms. But, being a good Army Soldier, I saluted and worked to make it happen. After all, maybe the research would bring some clinically useful revelations.

Lt. Gen. Chiarelli also wanted quick results, within a year. Fat chance, I would have muttered under my breath, had I not been a good Soldier.

So, what does the research tell us, 5 years after the inception? Frankly not much that a military psychiatrist does not already know about the risk factors for suicide in military members. However, the article in JAMA Psychiatry does quantify those risk factors mentioned above.

It also stresses the high risk for those recently psychiatrically hospitalized. Civilian as well as military psychiatrists already know that high-risk patients are the ones who get hospitalized. A caveat: Only 12% of Army suicides were post hospitalization.

However, for a military servicemember, the hospitalization may add to their stress, as it often contributes to an exit from the military. Exit may mean a loss of job, housing, health care, and identity.

What is the actionable intelligence from the article? By actionable intelligence, a military term, I mean here what can clinicians do differently as a result of the research? Do you hospitalize less? Probably not.

The authors suggest more posthospitalization interventions but are guarded in their recommendations. More intensive follow-up could lead to more stigmatization and contribute to an accelerated exit from the military.

Nevertheless, that recommendation is where the value of this article lies. The military system is highly stressed with many competing priorities. Many posts, but not all, have posthospitalization easy access to care. As the article recommends, and I concur, there should be more intensive follow-up. This can be done in many ways, including group settings; military members often prefer groups, as then they can help one another.

There is another subtext to the whole suicide discussion: In the early years of the wars in Iraq and Afghanistan, when the Army was desperate for recruits, it relaxed its accession standards. More came in with prior psychiatric diagnoses. Later, the standards were tightened again; those soldiers were disqualified.

The changes in accession standards often happen in times of conflict. It is not surprising that increases in behavioral health difficulties happen when recruiters are strapped for new recruits and take in marginal performers. Now that the military is drawing down, and it is harder to get into the military with a bad background, suicides in the active duty may taper, irrespective of all the research and suicide prevention programs.

So the article cements what we already knew: People with previous psychiatric problems are more likely to suicide. The question is what can we do about it?

Dr. Ritchie is former chief of psychiatry for the U.S. Army and the current chief clinical officer in the department of behavioral health for the District of Columbia.

I would like to provide some perspective on the recent article on the Army STARRS study.

The article, “Predicting Suicides After Psychiatric Hospitalization in U.S. Army Soldiers: The Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)” (JAMA Psychiatry 2014 Nov. 12 [doi: 10.1001/jamapsychiatry.2014.1754]), is one of a series from this multicenter, multiyear study.

Dr. Elspeth Cameron Ritchie

My observations focus on four areas: 1) the history behind this research effort, 2) what we learn from the results, 3) how can we change the way we treat service members based on the results? and 4) the change in accession standards.

This research effort was launched after the rate of suicides continued to rise. Then vice chief of staff, Lt. Gen. Peter Chiarelli was frustrated. He developed a contract with the National Institute of Mental Health to fund an ambitious research agenda that included examining all known suicides to find a way to reduce them.

At that time, I was the chief psychiatrist for the Army and was frankly cynical about the STARRS research. We already knew the risk factors for suicide: previous psychiatric or criminal history, relationship difficulties, problems at work, substance abuse, and access to firearms. But, being a good Army Soldier, I saluted and worked to make it happen. After all, maybe the research would bring some clinically useful revelations.

Lt. Gen. Chiarelli also wanted quick results, within a year. Fat chance, I would have muttered under my breath, had I not been a good Soldier.

So, what does the research tell us, 5 years after the inception? Frankly not much that a military psychiatrist does not already know about the risk factors for suicide in military members. However, the article in JAMA Psychiatry does quantify those risk factors mentioned above.

It also stresses the high risk for those recently psychiatrically hospitalized. Civilian as well as military psychiatrists already know that high-risk patients are the ones who get hospitalized. A caveat: Only 12% of Army suicides were post hospitalization.

However, for a military servicemember, the hospitalization may add to their stress, as it often contributes to an exit from the military. Exit may mean a loss of job, housing, health care, and identity.

What is the actionable intelligence from the article? By actionable intelligence, a military term, I mean here what can clinicians do differently as a result of the research? Do you hospitalize less? Probably not.

The authors suggest more posthospitalization interventions but are guarded in their recommendations. More intensive follow-up could lead to more stigmatization and contribute to an accelerated exit from the military.

Nevertheless, that recommendation is where the value of this article lies. The military system is highly stressed with many competing priorities. Many posts, but not all, have posthospitalization easy access to care. As the article recommends, and I concur, there should be more intensive follow-up. This can be done in many ways, including group settings; military members often prefer groups, as then they can help one another.

There is another subtext to the whole suicide discussion: In the early years of the wars in Iraq and Afghanistan, when the Army was desperate for recruits, it relaxed its accession standards. More came in with prior psychiatric diagnoses. Later, the standards were tightened again; those soldiers were disqualified.

The changes in accession standards often happen in times of conflict. It is not surprising that increases in behavioral health difficulties happen when recruiters are strapped for new recruits and take in marginal performers. Now that the military is drawing down, and it is harder to get into the military with a bad background, suicides in the active duty may taper, irrespective of all the research and suicide prevention programs.

So the article cements what we already knew: People with previous psychiatric problems are more likely to suicide. The question is what can we do about it?

Dr. Ritchie is former chief of psychiatry for the U.S. Army and the current chief clinical officer in the department of behavioral health for the District of Columbia.

References

References

Publications
Publications
Article Type
Display Headline
COMMENTARY: STARRS’ call for more intensive follow-up valuable
Display Headline
COMMENTARY: STARRS’ call for more intensive follow-up valuable
Legacy Keywords
Army suicides, STARRS, psychiatric hospitalization
Legacy Keywords
Army suicides, STARRS, psychiatric hospitalization
Sections
Article Source

PURLs Copyright

Inside the Article

Patient Safety: Innovation and Critical Thinking

Article Type
Changed
Display Headline
Patient Safety: Innovation and Critical Thinking

Preventable medical errors rank as the third most common cause of death in the United States after heart disease and cancer.1 They are responsible for 400,000 deaths each year (over 1095 per day) and another 10,000 serious complications resulting from medical errors each day.1 That is the equivalent of two 747 airliner midair crashes per day. The economic cost to our nation is $1 trillion per year.1

On July 17, 2014, the US Senate Subcommittee on Primary Health and Aging met to address this crisis. Participants included senators and John James, PhD, Founder, Patient Safety America, Houston, Texas; Ashish Jha, MD, MPH, Professor of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts; Tejal Gandhi, MD, MPH, President, National Patient Safety Foundation, and Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Peter Pronovost, MD, PhD, Senior Vice President for Patient Safety and Quality, and Director of the Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, Maryland; Joanne Disch, PhD, RN, Professor ad Honorem, University of Minnesota School of Nursing, Minneapolis, Minnesota; and Lisa McGiffert, Director, Safe Patient Project, Consumers Union, Austin, Texas. While each speaker suggested various strategies for improving patient safety, they all agreed that information technology is not living up to our expectations for meeting this need. They also agreed that health care has become increasingly “high tech and low touch,” and, as a result, the medical community is leveraging neither technology nor the knowledge accrued from individual patient/physician interactions to improve patient safety and outcomes.1

Last year my mother had a spinal fusion. The surgery was a success by all measures. Two days after she was discharged home, she became weak and was unable to walk. She went to the emergency room, where it was noted that she was severely hyponatremic, weak, and experiencing severe back pain. For the next 36 hours she was not seen by a physician or physician assistant (PA), as the PA who admitted her to the hospital had not notified the “team” that she was admitted. My father, who is a vascular surgeon, notified her spine surgeon, who came to see her. Her hyponatremia was markedly worse, and she was transferred to the intensive care unit (ICU). She continued to decline and was started on hypertonic intravenous (IV) saline. Over the next several days her hyponatremia improved, and she was transferred out of the ICU but continued to have pain. The spine surgeon examined her several times, and imaging showed no evidence of epidural bleeding, infection, or misplaced hardware.

Over the next several days, I was informed by family members that the nurses were “keeping the pain in check” with IV narcotics and that my mom was heavily sedated most of the time. My dad later informed me that she had a foot drop on the left, and the next day another family member told me the foot drop was on the right. My dad and stepbrother each assured me that they were right. When my mom could talk, she told me how weak she was and that sometimes it was her right leg and other times her left. She was seen by a neurologist on 6 out of the next 10 days and underwent 3 computed tomography scans and magnetic resonance imaging, and the neurologist assured us that she had not had a stroke. On a Friday evening, I called my mom, who was progressively short of breath, and she told me that she felt weaker and weaker each day. The “foot drop,” which was now bilateral according to the neurologist, was from “not using it while she was in the ICU.”

My mom, who is an artist, commented that she was having trouble using her hands now and unable to hold a cup. I called the physician on call, who assured me that she was taking care of my mom’s blood pressure (which was labile for the first time ever; she had no history of hypertension) and her pain score was a 5. I explained that I knew that she was not “looking to play mystery diagnosis with an orthopedic surgeon 500 miles away, but I think my mom has Guillain-Barré syndrome.” Fortunately, the doctor said, “Oh my god, I think you’re right.” Monday morning, her diagnosis was confirmed and she has made a remarkable recovery. So how is it that she could be seen by a neurologist and a team of nurses, doctors, therapists, and resident staff and no one made a diagnosis? Certainly contributing factors include a system of multiple medical teams with frequent turnovers and a desire to consult others but no real “quarterback” who was looking at the overall care in a responsible and critical way. A thorough history and physical examination, rather than a multitude of expensive and unnecessary imaging studies, could certainly have led to a quicker diagnosis and avoidance of a protracted hospital stay and rehabilitation.

 

 

To be sure, there are many factors that lead to delays in diagnosis. The reliance on advanced imaging, the lack of a simple physical examination, and the lack of critical thinking played prominently in the failure to make a diagnosis in my mom’s case. Some would argue that we need information technology (IT) systems that will allow us to better diagnose and treat patients. They believe that with electronic medical records (EMRs) data points will be entered and a diagnosis will be made. Major corporations like IBM and GE are working to make this a reality. Although Watson (the artificially intelligent computer system created by IBM) may be able to win on Jeopardy and may move the needle forward to improving patient care, 2 things are certain: (1) Appropriate data will need to be input by people, and (2) without critical thinking, the appropriate data can’t be entered or interpreted correctly. 

The fact remains that EMR has fallen short of expectations. We have more data at our fingertips but this has not translated into a significant improvement in patient safety. The human factor remains critical. Even though industry and health care workers strive to innovate and merge technological advances with improved patient outcomes, technology will continue to fall short of expectations without the input of critical thinking. There are things that computers and technological advances can do that people can’t, and there are things that people can do that computers can’t.

We cannot become a profession reliant on technology to substitute for critical thinking, and we cannot become a profession that doesn’t recognize what technology can bring to us and our patients. Like a railroad track that needs 2 parallel tracks to move trains, we must continue to build on 2 tracks: innovation and critical thinking. ◾

References

Reference

1. McCann E. Deaths by medical mistakes hit records. Healthcare IT News. http://www.healthcareitnews.com/news/deaths-by-medical-mistakes-hit-records. Published July 18, 2014. Accessed November 17, 2014.

Article PDF
Author and Disclosure Information

Albert J. Aboulafia, MD, FACS, MBA

Author’s Disclosure Statement: Dr. Aboulafia wishes to report that he owns stock in Amgen.

Issue
The American Journal of Orthopedics - 43(12)
Publications
Topics
Page Number
546-547
Legacy Keywords
american journal of orthopedics, AJO, guest editorial, editorial, patient safety, safety, patient, critical thinking, medical errors, technology, Aboulafia
Sections
Author and Disclosure Information

Albert J. Aboulafia, MD, FACS, MBA

Author’s Disclosure Statement: Dr. Aboulafia wishes to report that he owns stock in Amgen.

Author and Disclosure Information

Albert J. Aboulafia, MD, FACS, MBA

Author’s Disclosure Statement: Dr. Aboulafia wishes to report that he owns stock in Amgen.

Article PDF
Article PDF

Preventable medical errors rank as the third most common cause of death in the United States after heart disease and cancer.1 They are responsible for 400,000 deaths each year (over 1095 per day) and another 10,000 serious complications resulting from medical errors each day.1 That is the equivalent of two 747 airliner midair crashes per day. The economic cost to our nation is $1 trillion per year.1

On July 17, 2014, the US Senate Subcommittee on Primary Health and Aging met to address this crisis. Participants included senators and John James, PhD, Founder, Patient Safety America, Houston, Texas; Ashish Jha, MD, MPH, Professor of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts; Tejal Gandhi, MD, MPH, President, National Patient Safety Foundation, and Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Peter Pronovost, MD, PhD, Senior Vice President for Patient Safety and Quality, and Director of the Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, Maryland; Joanne Disch, PhD, RN, Professor ad Honorem, University of Minnesota School of Nursing, Minneapolis, Minnesota; and Lisa McGiffert, Director, Safe Patient Project, Consumers Union, Austin, Texas. While each speaker suggested various strategies for improving patient safety, they all agreed that information technology is not living up to our expectations for meeting this need. They also agreed that health care has become increasingly “high tech and low touch,” and, as a result, the medical community is leveraging neither technology nor the knowledge accrued from individual patient/physician interactions to improve patient safety and outcomes.1

Last year my mother had a spinal fusion. The surgery was a success by all measures. Two days after she was discharged home, she became weak and was unable to walk. She went to the emergency room, where it was noted that she was severely hyponatremic, weak, and experiencing severe back pain. For the next 36 hours she was not seen by a physician or physician assistant (PA), as the PA who admitted her to the hospital had not notified the “team” that she was admitted. My father, who is a vascular surgeon, notified her spine surgeon, who came to see her. Her hyponatremia was markedly worse, and she was transferred to the intensive care unit (ICU). She continued to decline and was started on hypertonic intravenous (IV) saline. Over the next several days her hyponatremia improved, and she was transferred out of the ICU but continued to have pain. The spine surgeon examined her several times, and imaging showed no evidence of epidural bleeding, infection, or misplaced hardware.

Over the next several days, I was informed by family members that the nurses were “keeping the pain in check” with IV narcotics and that my mom was heavily sedated most of the time. My dad later informed me that she had a foot drop on the left, and the next day another family member told me the foot drop was on the right. My dad and stepbrother each assured me that they were right. When my mom could talk, she told me how weak she was and that sometimes it was her right leg and other times her left. She was seen by a neurologist on 6 out of the next 10 days and underwent 3 computed tomography scans and magnetic resonance imaging, and the neurologist assured us that she had not had a stroke. On a Friday evening, I called my mom, who was progressively short of breath, and she told me that she felt weaker and weaker each day. The “foot drop,” which was now bilateral according to the neurologist, was from “not using it while she was in the ICU.”

My mom, who is an artist, commented that she was having trouble using her hands now and unable to hold a cup. I called the physician on call, who assured me that she was taking care of my mom’s blood pressure (which was labile for the first time ever; she had no history of hypertension) and her pain score was a 5. I explained that I knew that she was not “looking to play mystery diagnosis with an orthopedic surgeon 500 miles away, but I think my mom has Guillain-Barré syndrome.” Fortunately, the doctor said, “Oh my god, I think you’re right.” Monday morning, her diagnosis was confirmed and she has made a remarkable recovery. So how is it that she could be seen by a neurologist and a team of nurses, doctors, therapists, and resident staff and no one made a diagnosis? Certainly contributing factors include a system of multiple medical teams with frequent turnovers and a desire to consult others but no real “quarterback” who was looking at the overall care in a responsible and critical way. A thorough history and physical examination, rather than a multitude of expensive and unnecessary imaging studies, could certainly have led to a quicker diagnosis and avoidance of a protracted hospital stay and rehabilitation.

 

 

To be sure, there are many factors that lead to delays in diagnosis. The reliance on advanced imaging, the lack of a simple physical examination, and the lack of critical thinking played prominently in the failure to make a diagnosis in my mom’s case. Some would argue that we need information technology (IT) systems that will allow us to better diagnose and treat patients. They believe that with electronic medical records (EMRs) data points will be entered and a diagnosis will be made. Major corporations like IBM and GE are working to make this a reality. Although Watson (the artificially intelligent computer system created by IBM) may be able to win on Jeopardy and may move the needle forward to improving patient care, 2 things are certain: (1) Appropriate data will need to be input by people, and (2) without critical thinking, the appropriate data can’t be entered or interpreted correctly. 

The fact remains that EMR has fallen short of expectations. We have more data at our fingertips but this has not translated into a significant improvement in patient safety. The human factor remains critical. Even though industry and health care workers strive to innovate and merge technological advances with improved patient outcomes, technology will continue to fall short of expectations without the input of critical thinking. There are things that computers and technological advances can do that people can’t, and there are things that people can do that computers can’t.

We cannot become a profession reliant on technology to substitute for critical thinking, and we cannot become a profession that doesn’t recognize what technology can bring to us and our patients. Like a railroad track that needs 2 parallel tracks to move trains, we must continue to build on 2 tracks: innovation and critical thinking. ◾

Preventable medical errors rank as the third most common cause of death in the United States after heart disease and cancer.1 They are responsible for 400,000 deaths each year (over 1095 per day) and another 10,000 serious complications resulting from medical errors each day.1 That is the equivalent of two 747 airliner midair crashes per day. The economic cost to our nation is $1 trillion per year.1

On July 17, 2014, the US Senate Subcommittee on Primary Health and Aging met to address this crisis. Participants included senators and John James, PhD, Founder, Patient Safety America, Houston, Texas; Ashish Jha, MD, MPH, Professor of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts; Tejal Gandhi, MD, MPH, President, National Patient Safety Foundation, and Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Peter Pronovost, MD, PhD, Senior Vice President for Patient Safety and Quality, and Director of the Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, Maryland; Joanne Disch, PhD, RN, Professor ad Honorem, University of Minnesota School of Nursing, Minneapolis, Minnesota; and Lisa McGiffert, Director, Safe Patient Project, Consumers Union, Austin, Texas. While each speaker suggested various strategies for improving patient safety, they all agreed that information technology is not living up to our expectations for meeting this need. They also agreed that health care has become increasingly “high tech and low touch,” and, as a result, the medical community is leveraging neither technology nor the knowledge accrued from individual patient/physician interactions to improve patient safety and outcomes.1

Last year my mother had a spinal fusion. The surgery was a success by all measures. Two days after she was discharged home, she became weak and was unable to walk. She went to the emergency room, where it was noted that she was severely hyponatremic, weak, and experiencing severe back pain. For the next 36 hours she was not seen by a physician or physician assistant (PA), as the PA who admitted her to the hospital had not notified the “team” that she was admitted. My father, who is a vascular surgeon, notified her spine surgeon, who came to see her. Her hyponatremia was markedly worse, and she was transferred to the intensive care unit (ICU). She continued to decline and was started on hypertonic intravenous (IV) saline. Over the next several days her hyponatremia improved, and she was transferred out of the ICU but continued to have pain. The spine surgeon examined her several times, and imaging showed no evidence of epidural bleeding, infection, or misplaced hardware.

Over the next several days, I was informed by family members that the nurses were “keeping the pain in check” with IV narcotics and that my mom was heavily sedated most of the time. My dad later informed me that she had a foot drop on the left, and the next day another family member told me the foot drop was on the right. My dad and stepbrother each assured me that they were right. When my mom could talk, she told me how weak she was and that sometimes it was her right leg and other times her left. She was seen by a neurologist on 6 out of the next 10 days and underwent 3 computed tomography scans and magnetic resonance imaging, and the neurologist assured us that she had not had a stroke. On a Friday evening, I called my mom, who was progressively short of breath, and she told me that she felt weaker and weaker each day. The “foot drop,” which was now bilateral according to the neurologist, was from “not using it while she was in the ICU.”

My mom, who is an artist, commented that she was having trouble using her hands now and unable to hold a cup. I called the physician on call, who assured me that she was taking care of my mom’s blood pressure (which was labile for the first time ever; she had no history of hypertension) and her pain score was a 5. I explained that I knew that she was not “looking to play mystery diagnosis with an orthopedic surgeon 500 miles away, but I think my mom has Guillain-Barré syndrome.” Fortunately, the doctor said, “Oh my god, I think you’re right.” Monday morning, her diagnosis was confirmed and she has made a remarkable recovery. So how is it that she could be seen by a neurologist and a team of nurses, doctors, therapists, and resident staff and no one made a diagnosis? Certainly contributing factors include a system of multiple medical teams with frequent turnovers and a desire to consult others but no real “quarterback” who was looking at the overall care in a responsible and critical way. A thorough history and physical examination, rather than a multitude of expensive and unnecessary imaging studies, could certainly have led to a quicker diagnosis and avoidance of a protracted hospital stay and rehabilitation.

 

 

To be sure, there are many factors that lead to delays in diagnosis. The reliance on advanced imaging, the lack of a simple physical examination, and the lack of critical thinking played prominently in the failure to make a diagnosis in my mom’s case. Some would argue that we need information technology (IT) systems that will allow us to better diagnose and treat patients. They believe that with electronic medical records (EMRs) data points will be entered and a diagnosis will be made. Major corporations like IBM and GE are working to make this a reality. Although Watson (the artificially intelligent computer system created by IBM) may be able to win on Jeopardy and may move the needle forward to improving patient care, 2 things are certain: (1) Appropriate data will need to be input by people, and (2) without critical thinking, the appropriate data can’t be entered or interpreted correctly. 

The fact remains that EMR has fallen short of expectations. We have more data at our fingertips but this has not translated into a significant improvement in patient safety. The human factor remains critical. Even though industry and health care workers strive to innovate and merge technological advances with improved patient outcomes, technology will continue to fall short of expectations without the input of critical thinking. There are things that computers and technological advances can do that people can’t, and there are things that people can do that computers can’t.

We cannot become a profession reliant on technology to substitute for critical thinking, and we cannot become a profession that doesn’t recognize what technology can bring to us and our patients. Like a railroad track that needs 2 parallel tracks to move trains, we must continue to build on 2 tracks: innovation and critical thinking. ◾

References

Reference

1. McCann E. Deaths by medical mistakes hit records. Healthcare IT News. http://www.healthcareitnews.com/news/deaths-by-medical-mistakes-hit-records. Published July 18, 2014. Accessed November 17, 2014.

References

Reference

1. McCann E. Deaths by medical mistakes hit records. Healthcare IT News. http://www.healthcareitnews.com/news/deaths-by-medical-mistakes-hit-records. Published July 18, 2014. Accessed November 17, 2014.

Issue
The American Journal of Orthopedics - 43(12)
Issue
The American Journal of Orthopedics - 43(12)
Page Number
546-547
Page Number
546-547
Publications
Publications
Topics
Article Type
Display Headline
Patient Safety: Innovation and Critical Thinking
Display Headline
Patient Safety: Innovation and Critical Thinking
Legacy Keywords
american journal of orthopedics, AJO, guest editorial, editorial, patient safety, safety, patient, critical thinking, medical errors, technology, Aboulafia
Legacy Keywords
american journal of orthopedics, AJO, guest editorial, editorial, patient safety, safety, patient, critical thinking, medical errors, technology, Aboulafia
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Midurethral slings

Article Type
Changed
Display Headline
Midurethral slings

Minimally invasive synthetic midurethral slings may be considered the standard of care for the surgical treatment of stress urinary incontinence – and a first-line treatment for severe cases of the condition – based on the publication of numerous level 1 randomized trials, high-quality reviews, and recent position statements from professional societies.

The current evidence base shows that midurethral sling operations are as effective as bladder neck slings and colposuspension, with less morbidity. Operating times are shorter, and local anesthesia is possible. Compared with pubovaginal slings, which are fixed at the bladder neck, midurethral slings are associated with less postoperative voiding dysfunction and fewer de novo urgency symptoms.

Dr. Eric R. Sokol

Midurethral slings (MUS) also have been shown to be more successful – and more cost-effective – than pelvic floor physiotherapy for stress urinary incontinence (SUI) overall, with the possible exception of mild SUI.

Physiotherapy involving pelvic floor muscle therapy has long been advocated as a first-line treatment for SUI, with MUS surgery often recommended when physiotherapy is unsuccessful. In recent years, however, with high success rates for MUS, the role of physiotherapy as a first-line treatment has become more debatable.

A multicenter randomized trial in 660 women published last year in the New England Journal of Medicine substantiated what many of us have seen in our practices and in other published studies: significantly lower rates of improvement and cure with initial physiotherapy than with primary surgery.

Initial MUS surgery resulted in higher rates of subjective improvement, compared with initial physiotherapy (91% vs. 64%), subjective cure (85% v. 53%), and objective cure (77% v. 59%) at 1 year. Moreover, a significant number of women – 49% – chose to abandon conservative therapy and have MUS surgery for their SUI during the study period (N. Engl. J. Med. 2013;369:1124-33).

A joint position statement published in early 2014 by the American Urogynecologic Society (AUGS) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) calls MUS the most extensively studied anti-incontinence procedure and “probably the most important advancement in the treatment of SUI in the last 50 years.” More than 2,000 publications in the literature have described the procedure for SUI, and multiple randomized controlled trials have compared various types of MUS procedures as well as MUS to other nonmesh SUI procedures, the statement says.

My colleague and I recently modeled the cost-effectiveness of pelvic floor muscle therapy and continence pessaries vs. surgical treatment with MUS for initial treatment of SUI. Initial treatment with MUS was the best strategy, with an incremental cost-effectiveness ratio of $32,132 per quality-adjusted life-year, compared with initial treatment with pelvic floor muscle therapy. Under our model, treatment with a continence pessary would never be the preferred choice due to low subjective cure rates (Am. J. Obstet. Gynecol. 2014;211:565.e1-6).

I now tell patients who present with a history of severe stress incontinence, and who leak on a cough stress test, that a trial of pelvic floor physiotherapy is an option but one with a lower likelihood of success. I recommend an MUS as primary treatment for these patients, and the question then often becomes which sling to use.

Sling selection

There are two broad approaches to MUS surgery – retropubic and transobturator – and within each approach, there are different routes for the delivery of the polypropylene mesh sling.

Retropubic slings. Retropubic slings are passed transvaginally at the midurethral level through the retropubic space. Tension-free vaginal tape (TVT) has been used in millions of women worldwide, with good long-term outcomes, since it was introduced by Dr. Ulf Ulmsten in 1995. The TVT procedure utilizes a bottom-up approach, with curved needles being passed from a small vaginal incision up through the retropubic space to exit through two suprapubic incisions.

A second type of retropubic sling – the suprapubic urethral support sling (SPARC, American Medical Systems) – utilizes a downward-pass, or top-down, approach in which a metal trocar is passed through suprapubic incisions and down through the retropubic space to exit a vaginal incision.

The theoretical advantages of this modification to the TVT procedure have included more control over the needle introducer near the rectus fascia, and a lower risk of bowel and vascular injury. However, comparisons during the last decade of the two retropubic approaches have suggested slightly better outcomes – relating both to cure rates and to complication rates – with TVT compared with SPARC.

A Cochrane Review published in 2009, titled “Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women,” provided higher-level evidence in favor of bottom-up slings. A sub-meta-analysis of five randomized controlled trials – part of a broader intervention review – showed that a retropubic bottom-up approach was more effective than a top-down route (risk ratio, 1.10), with higher subjective and objective SUI cure rates (Cochrane Database Syst. Rev. 2009(4): CD006375). There also was significantly less bladder perforation, less mesh erosion, and less voiding dysfunction.

 

 

TVT slings, therefore, appear to be somewhat superior, with statistically significant differences in each of the domains of efficacy and morbidity. Still, surgeon experience and skill remain factors in sling selection; the surgeon who feels comfortable and skilled with a top-down approach and has little experience with a bottom-up approach should continue with SPARC. For surgeons who are skilled with both approaches, it might well be preferable to favor TVT.

Transobturator slings. The transobturator approach was developed to minimize the potential for bladder and bowel injuries by avoiding the pelvic organs in the retropubic space. The sling is introduced either through an inside-out technique, with the needle passed from a vaginal incision and out through the obturator foramen, or through an outside-in technique, with the needle passed through the thigh and then out through the vaginal incision.

A meta-analysis of trials of transobturator sling procedures – including four direct-comparison, randomized controlled trials of the inside-out technique vs. the outside-in technique – showed no significant differences between the two approaches in subjective and objective SUI cure rates in the short term. Rates of postoperative voiding difficulties and de novo urgency symptoms were similar (BJU Int. 2010;106:68-76).

Making a choice. Each of the currently available midurethral slings appears to work well, overall, with few clinically significant differences in outcomes. On the other hand, midurethral slings are not all the same. It is important to appreciate the more subtle differences, to be aware of the evidence, and to be appropriately trained. Often, sling selection involves weighing the risks and benefits for the individual.

On a broad scale, the most recent high-level comparison of the retropubic and transobturator slings appears to be a meta-analysis in which retropubic midurethral slings showed better objective and subjective cure rates than transobturator midurethral slings. Women treated with retropubic slings had a 35% higher odds of objective cure and a 24% higher odds of subjective cure. (The weighted average objective cure rates were 87% for retropubic slings vs. 83% for transobturator slings with a weighted average follow-up of approximately 17 months. The weighted average subjective cure rates were 76% and 73%, respectively.)

Operating times were longer with retropubic slings, but lengths of stay were equivalent between the two types of procedures. This was based on 17 studies of about 3,000 women (J. Urology 2014 [doi: 10.1016/j.juro.2014.09.104]).

The types of complications seen with each approach differed. Bladder perforation was significantly more common with retropubic slings (3.2% vs. 0.2%), as was bleeding (3.2% v. 1.1%). Transobturator slings were associated with more cases of neurologic symptoms (9.4% v. 3.5%) and vaginal perforation (3.6% v. 0.9%).

This new review provides updated information to the 2009 Cochrane Review mentioned above, which reported that women were less likely to be continent after operations performed via the obturator route, but also less likely to have encountered complications. More specifically, objective cure rates were slightly higher with retropubic slings than with transobturator slings (88% vs. 84%) in the 2009 review. There was no difference in subjective cure rates. With the obturator route, there was less voiding dysfunction, blood loss, and bladder perforation (0.3% v. 5.5%).

Other pivotal trials since the 2009 Cochrane Review include a multicenter randomized equivalence trial published in the New England Journal of Medicine in 2010. The trial randomized 597 women to transobturator or retropubic sling surgery, and found no significant differences in subjective success (56% vs. 62%) or in objective success (78% vs. 81%) at 12 months (N. Engl. J. Med. 2010;362:2066-76).

There is some level 1 evidence suggesting that for severe incontinence involving intrinsic sphincter deficiency (ISD), a retropubic TVT sling is the more effective procedure. A randomized trial of 164 women with urodynamic SUI and ISD, for instance, found that 21% of those in the TVT group and 45% of those in the transobturator group had urodynamic SUI 6 months postoperatively.

The risk ratio of repeat surgery was 2.6 times higher in the transobturator group than in the retropubic TVT group (Obstet. Gynecol. 2008;112:1253-61). TVT was more effective both with and without concurrent pelvic organ prolapse repair.

I tell my patients with severe SUI or ISD, therefore, that retropubic sling procedures appear to be preferable. (Exceptions include the patient who has a history of retropubic surgeries, in whom passing the sling through this route may not be the safest approach, as well as the patient who has had mesh erosion into the bladder.)

In patients whose SUI is less severe, I counsel that a transobturator sling confers satisfaction rates similar to those of a retropubic sling and has a lower risk of complications, such as postoperative voiding dysfunction and bladder perforations, but with the possible trade-off of more thigh discomfort. I also might recommend a transobturator sling to patients with more pronounced initial complaints of urinary urgency and frequency, and to patients who have minor voiding dysfunction or a low level of incomplete bladder emptying.

 

 

While often short-lived, the small risk of thigh pain with a transobturator sling makes me less likely to recommend this type of sling for a woman who is a marathon runner or competitive athlete. In her case, an analysis of possible complications includes the consideration that bladder perforation can be addressed relatively quickly in the operating room, while persistent thigh discomfort, though relatively rare, could be a debilitating problem.

Single-incision slings

There appears to be emerging evidence suggesting that some of the fixed and adjustable single-incision slings currently available may have efficacy similar to that of the slings that are now widely used.

A Cochrane Review presented at the 2014 AUGS-IUGA scientific meeting and published this summer concludes that there is not enough evidence on single-incision slings compared with retropubic or transobturator slings to allow reliable comparisons, and that additional, adequately powered, high-quality trials with longer-term follow-up are needed (Cochrane Database Sys. Rev. 2014;6:CD008709). However, research completed since the review offers additional data.

For instance, at the 2014 AUGS-IUGA scientific meeting this summer, an oral paper presentation highlighted findings of a randomized controlled trial that showed similar cure rates after surgery with the MiniArc, a fixed single-incision sling, and the Monarc transobturator sling (both by American Medical Systems) at 24 months. The study randomized 234 women to either sling and found no significant differences in subjective outcomes, objective outcomes, or results on various quality-of-life questionnaires.

As such studies are published and more evidence emerges, we will gain a clearer picture of how the newer single-incision slings compare to the well-tested retropubic and transobturator slings with respect to efficacy and safety.

Single-incision slings require only a small vaginal incision and no exit points. Without abdominal or thigh incisions, these new procedures – intended for less severe SUI (no ISD) – may offer improved perioperative and postoperative patient comfort and a potentially decreased risk of surgical injury to the adductor muscles, as well as a decreased risk of vascular and nerve injury. Candidates for these slings may include those who are very athletic, those who are obese, and those with a history of prior retropubic or pelvic surgery.

Research appears to be progressing, but at this time we do not yet have level 1 evidence to support their routine use.

Dr. Sokol reported that he owns stock in Pelvalon, and is a clinical adviser to that company. He also is a national principal investigator for American Medical Systems, and the recipient of research grants from Acell and several other companies.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
midurethral slings, tranobturator, retropublic, stress urinary incontinence
Sections
Author and Disclosure Information

Author and Disclosure Information

Related Articles

Minimally invasive synthetic midurethral slings may be considered the standard of care for the surgical treatment of stress urinary incontinence – and a first-line treatment for severe cases of the condition – based on the publication of numerous level 1 randomized trials, high-quality reviews, and recent position statements from professional societies.

The current evidence base shows that midurethral sling operations are as effective as bladder neck slings and colposuspension, with less morbidity. Operating times are shorter, and local anesthesia is possible. Compared with pubovaginal slings, which are fixed at the bladder neck, midurethral slings are associated with less postoperative voiding dysfunction and fewer de novo urgency symptoms.

Dr. Eric R. Sokol

Midurethral slings (MUS) also have been shown to be more successful – and more cost-effective – than pelvic floor physiotherapy for stress urinary incontinence (SUI) overall, with the possible exception of mild SUI.

Physiotherapy involving pelvic floor muscle therapy has long been advocated as a first-line treatment for SUI, with MUS surgery often recommended when physiotherapy is unsuccessful. In recent years, however, with high success rates for MUS, the role of physiotherapy as a first-line treatment has become more debatable.

A multicenter randomized trial in 660 women published last year in the New England Journal of Medicine substantiated what many of us have seen in our practices and in other published studies: significantly lower rates of improvement and cure with initial physiotherapy than with primary surgery.

Initial MUS surgery resulted in higher rates of subjective improvement, compared with initial physiotherapy (91% vs. 64%), subjective cure (85% v. 53%), and objective cure (77% v. 59%) at 1 year. Moreover, a significant number of women – 49% – chose to abandon conservative therapy and have MUS surgery for their SUI during the study period (N. Engl. J. Med. 2013;369:1124-33).

A joint position statement published in early 2014 by the American Urogynecologic Society (AUGS) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) calls MUS the most extensively studied anti-incontinence procedure and “probably the most important advancement in the treatment of SUI in the last 50 years.” More than 2,000 publications in the literature have described the procedure for SUI, and multiple randomized controlled trials have compared various types of MUS procedures as well as MUS to other nonmesh SUI procedures, the statement says.

My colleague and I recently modeled the cost-effectiveness of pelvic floor muscle therapy and continence pessaries vs. surgical treatment with MUS for initial treatment of SUI. Initial treatment with MUS was the best strategy, with an incremental cost-effectiveness ratio of $32,132 per quality-adjusted life-year, compared with initial treatment with pelvic floor muscle therapy. Under our model, treatment with a continence pessary would never be the preferred choice due to low subjective cure rates (Am. J. Obstet. Gynecol. 2014;211:565.e1-6).

I now tell patients who present with a history of severe stress incontinence, and who leak on a cough stress test, that a trial of pelvic floor physiotherapy is an option but one with a lower likelihood of success. I recommend an MUS as primary treatment for these patients, and the question then often becomes which sling to use.

Sling selection

There are two broad approaches to MUS surgery – retropubic and transobturator – and within each approach, there are different routes for the delivery of the polypropylene mesh sling.

Retropubic slings. Retropubic slings are passed transvaginally at the midurethral level through the retropubic space. Tension-free vaginal tape (TVT) has been used in millions of women worldwide, with good long-term outcomes, since it was introduced by Dr. Ulf Ulmsten in 1995. The TVT procedure utilizes a bottom-up approach, with curved needles being passed from a small vaginal incision up through the retropubic space to exit through two suprapubic incisions.

A second type of retropubic sling – the suprapubic urethral support sling (SPARC, American Medical Systems) – utilizes a downward-pass, or top-down, approach in which a metal trocar is passed through suprapubic incisions and down through the retropubic space to exit a vaginal incision.

The theoretical advantages of this modification to the TVT procedure have included more control over the needle introducer near the rectus fascia, and a lower risk of bowel and vascular injury. However, comparisons during the last decade of the two retropubic approaches have suggested slightly better outcomes – relating both to cure rates and to complication rates – with TVT compared with SPARC.

A Cochrane Review published in 2009, titled “Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women,” provided higher-level evidence in favor of bottom-up slings. A sub-meta-analysis of five randomized controlled trials – part of a broader intervention review – showed that a retropubic bottom-up approach was more effective than a top-down route (risk ratio, 1.10), with higher subjective and objective SUI cure rates (Cochrane Database Syst. Rev. 2009(4): CD006375). There also was significantly less bladder perforation, less mesh erosion, and less voiding dysfunction.

 

 

TVT slings, therefore, appear to be somewhat superior, with statistically significant differences in each of the domains of efficacy and morbidity. Still, surgeon experience and skill remain factors in sling selection; the surgeon who feels comfortable and skilled with a top-down approach and has little experience with a bottom-up approach should continue with SPARC. For surgeons who are skilled with both approaches, it might well be preferable to favor TVT.

Transobturator slings. The transobturator approach was developed to minimize the potential for bladder and bowel injuries by avoiding the pelvic organs in the retropubic space. The sling is introduced either through an inside-out technique, with the needle passed from a vaginal incision and out through the obturator foramen, or through an outside-in technique, with the needle passed through the thigh and then out through the vaginal incision.

A meta-analysis of trials of transobturator sling procedures – including four direct-comparison, randomized controlled trials of the inside-out technique vs. the outside-in technique – showed no significant differences between the two approaches in subjective and objective SUI cure rates in the short term. Rates of postoperative voiding difficulties and de novo urgency symptoms were similar (BJU Int. 2010;106:68-76).

Making a choice. Each of the currently available midurethral slings appears to work well, overall, with few clinically significant differences in outcomes. On the other hand, midurethral slings are not all the same. It is important to appreciate the more subtle differences, to be aware of the evidence, and to be appropriately trained. Often, sling selection involves weighing the risks and benefits for the individual.

On a broad scale, the most recent high-level comparison of the retropubic and transobturator slings appears to be a meta-analysis in which retropubic midurethral slings showed better objective and subjective cure rates than transobturator midurethral slings. Women treated with retropubic slings had a 35% higher odds of objective cure and a 24% higher odds of subjective cure. (The weighted average objective cure rates were 87% for retropubic slings vs. 83% for transobturator slings with a weighted average follow-up of approximately 17 months. The weighted average subjective cure rates were 76% and 73%, respectively.)

Operating times were longer with retropubic slings, but lengths of stay were equivalent between the two types of procedures. This was based on 17 studies of about 3,000 women (J. Urology 2014 [doi: 10.1016/j.juro.2014.09.104]).

The types of complications seen with each approach differed. Bladder perforation was significantly more common with retropubic slings (3.2% vs. 0.2%), as was bleeding (3.2% v. 1.1%). Transobturator slings were associated with more cases of neurologic symptoms (9.4% v. 3.5%) and vaginal perforation (3.6% v. 0.9%).

This new review provides updated information to the 2009 Cochrane Review mentioned above, which reported that women were less likely to be continent after operations performed via the obturator route, but also less likely to have encountered complications. More specifically, objective cure rates were slightly higher with retropubic slings than with transobturator slings (88% vs. 84%) in the 2009 review. There was no difference in subjective cure rates. With the obturator route, there was less voiding dysfunction, blood loss, and bladder perforation (0.3% v. 5.5%).

Other pivotal trials since the 2009 Cochrane Review include a multicenter randomized equivalence trial published in the New England Journal of Medicine in 2010. The trial randomized 597 women to transobturator or retropubic sling surgery, and found no significant differences in subjective success (56% vs. 62%) or in objective success (78% vs. 81%) at 12 months (N. Engl. J. Med. 2010;362:2066-76).

There is some level 1 evidence suggesting that for severe incontinence involving intrinsic sphincter deficiency (ISD), a retropubic TVT sling is the more effective procedure. A randomized trial of 164 women with urodynamic SUI and ISD, for instance, found that 21% of those in the TVT group and 45% of those in the transobturator group had urodynamic SUI 6 months postoperatively.

The risk ratio of repeat surgery was 2.6 times higher in the transobturator group than in the retropubic TVT group (Obstet. Gynecol. 2008;112:1253-61). TVT was more effective both with and without concurrent pelvic organ prolapse repair.

I tell my patients with severe SUI or ISD, therefore, that retropubic sling procedures appear to be preferable. (Exceptions include the patient who has a history of retropubic surgeries, in whom passing the sling through this route may not be the safest approach, as well as the patient who has had mesh erosion into the bladder.)

In patients whose SUI is less severe, I counsel that a transobturator sling confers satisfaction rates similar to those of a retropubic sling and has a lower risk of complications, such as postoperative voiding dysfunction and bladder perforations, but with the possible trade-off of more thigh discomfort. I also might recommend a transobturator sling to patients with more pronounced initial complaints of urinary urgency and frequency, and to patients who have minor voiding dysfunction or a low level of incomplete bladder emptying.

 

 

While often short-lived, the small risk of thigh pain with a transobturator sling makes me less likely to recommend this type of sling for a woman who is a marathon runner or competitive athlete. In her case, an analysis of possible complications includes the consideration that bladder perforation can be addressed relatively quickly in the operating room, while persistent thigh discomfort, though relatively rare, could be a debilitating problem.

Single-incision slings

There appears to be emerging evidence suggesting that some of the fixed and adjustable single-incision slings currently available may have efficacy similar to that of the slings that are now widely used.

A Cochrane Review presented at the 2014 AUGS-IUGA scientific meeting and published this summer concludes that there is not enough evidence on single-incision slings compared with retropubic or transobturator slings to allow reliable comparisons, and that additional, adequately powered, high-quality trials with longer-term follow-up are needed (Cochrane Database Sys. Rev. 2014;6:CD008709). However, research completed since the review offers additional data.

For instance, at the 2014 AUGS-IUGA scientific meeting this summer, an oral paper presentation highlighted findings of a randomized controlled trial that showed similar cure rates after surgery with the MiniArc, a fixed single-incision sling, and the Monarc transobturator sling (both by American Medical Systems) at 24 months. The study randomized 234 women to either sling and found no significant differences in subjective outcomes, objective outcomes, or results on various quality-of-life questionnaires.

As such studies are published and more evidence emerges, we will gain a clearer picture of how the newer single-incision slings compare to the well-tested retropubic and transobturator slings with respect to efficacy and safety.

Single-incision slings require only a small vaginal incision and no exit points. Without abdominal or thigh incisions, these new procedures – intended for less severe SUI (no ISD) – may offer improved perioperative and postoperative patient comfort and a potentially decreased risk of surgical injury to the adductor muscles, as well as a decreased risk of vascular and nerve injury. Candidates for these slings may include those who are very athletic, those who are obese, and those with a history of prior retropubic or pelvic surgery.

Research appears to be progressing, but at this time we do not yet have level 1 evidence to support their routine use.

Dr. Sokol reported that he owns stock in Pelvalon, and is a clinical adviser to that company. He also is a national principal investigator for American Medical Systems, and the recipient of research grants from Acell and several other companies.

Minimally invasive synthetic midurethral slings may be considered the standard of care for the surgical treatment of stress urinary incontinence – and a first-line treatment for severe cases of the condition – based on the publication of numerous level 1 randomized trials, high-quality reviews, and recent position statements from professional societies.

The current evidence base shows that midurethral sling operations are as effective as bladder neck slings and colposuspension, with less morbidity. Operating times are shorter, and local anesthesia is possible. Compared with pubovaginal slings, which are fixed at the bladder neck, midurethral slings are associated with less postoperative voiding dysfunction and fewer de novo urgency symptoms.

Dr. Eric R. Sokol

Midurethral slings (MUS) also have been shown to be more successful – and more cost-effective – than pelvic floor physiotherapy for stress urinary incontinence (SUI) overall, with the possible exception of mild SUI.

Physiotherapy involving pelvic floor muscle therapy has long been advocated as a first-line treatment for SUI, with MUS surgery often recommended when physiotherapy is unsuccessful. In recent years, however, with high success rates for MUS, the role of physiotherapy as a first-line treatment has become more debatable.

A multicenter randomized trial in 660 women published last year in the New England Journal of Medicine substantiated what many of us have seen in our practices and in other published studies: significantly lower rates of improvement and cure with initial physiotherapy than with primary surgery.

Initial MUS surgery resulted in higher rates of subjective improvement, compared with initial physiotherapy (91% vs. 64%), subjective cure (85% v. 53%), and objective cure (77% v. 59%) at 1 year. Moreover, a significant number of women – 49% – chose to abandon conservative therapy and have MUS surgery for their SUI during the study period (N. Engl. J. Med. 2013;369:1124-33).

A joint position statement published in early 2014 by the American Urogynecologic Society (AUGS) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) calls MUS the most extensively studied anti-incontinence procedure and “probably the most important advancement in the treatment of SUI in the last 50 years.” More than 2,000 publications in the literature have described the procedure for SUI, and multiple randomized controlled trials have compared various types of MUS procedures as well as MUS to other nonmesh SUI procedures, the statement says.

My colleague and I recently modeled the cost-effectiveness of pelvic floor muscle therapy and continence pessaries vs. surgical treatment with MUS for initial treatment of SUI. Initial treatment with MUS was the best strategy, with an incremental cost-effectiveness ratio of $32,132 per quality-adjusted life-year, compared with initial treatment with pelvic floor muscle therapy. Under our model, treatment with a continence pessary would never be the preferred choice due to low subjective cure rates (Am. J. Obstet. Gynecol. 2014;211:565.e1-6).

I now tell patients who present with a history of severe stress incontinence, and who leak on a cough stress test, that a trial of pelvic floor physiotherapy is an option but one with a lower likelihood of success. I recommend an MUS as primary treatment for these patients, and the question then often becomes which sling to use.

Sling selection

There are two broad approaches to MUS surgery – retropubic and transobturator – and within each approach, there are different routes for the delivery of the polypropylene mesh sling.

Retropubic slings. Retropubic slings are passed transvaginally at the midurethral level through the retropubic space. Tension-free vaginal tape (TVT) has been used in millions of women worldwide, with good long-term outcomes, since it was introduced by Dr. Ulf Ulmsten in 1995. The TVT procedure utilizes a bottom-up approach, with curved needles being passed from a small vaginal incision up through the retropubic space to exit through two suprapubic incisions.

A second type of retropubic sling – the suprapubic urethral support sling (SPARC, American Medical Systems) – utilizes a downward-pass, or top-down, approach in which a metal trocar is passed through suprapubic incisions and down through the retropubic space to exit a vaginal incision.

The theoretical advantages of this modification to the TVT procedure have included more control over the needle introducer near the rectus fascia, and a lower risk of bowel and vascular injury. However, comparisons during the last decade of the two retropubic approaches have suggested slightly better outcomes – relating both to cure rates and to complication rates – with TVT compared with SPARC.

A Cochrane Review published in 2009, titled “Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women,” provided higher-level evidence in favor of bottom-up slings. A sub-meta-analysis of five randomized controlled trials – part of a broader intervention review – showed that a retropubic bottom-up approach was more effective than a top-down route (risk ratio, 1.10), with higher subjective and objective SUI cure rates (Cochrane Database Syst. Rev. 2009(4): CD006375). There also was significantly less bladder perforation, less mesh erosion, and less voiding dysfunction.

 

 

TVT slings, therefore, appear to be somewhat superior, with statistically significant differences in each of the domains of efficacy and morbidity. Still, surgeon experience and skill remain factors in sling selection; the surgeon who feels comfortable and skilled with a top-down approach and has little experience with a bottom-up approach should continue with SPARC. For surgeons who are skilled with both approaches, it might well be preferable to favor TVT.

Transobturator slings. The transobturator approach was developed to minimize the potential for bladder and bowel injuries by avoiding the pelvic organs in the retropubic space. The sling is introduced either through an inside-out technique, with the needle passed from a vaginal incision and out through the obturator foramen, or through an outside-in technique, with the needle passed through the thigh and then out through the vaginal incision.

A meta-analysis of trials of transobturator sling procedures – including four direct-comparison, randomized controlled trials of the inside-out technique vs. the outside-in technique – showed no significant differences between the two approaches in subjective and objective SUI cure rates in the short term. Rates of postoperative voiding difficulties and de novo urgency symptoms were similar (BJU Int. 2010;106:68-76).

Making a choice. Each of the currently available midurethral slings appears to work well, overall, with few clinically significant differences in outcomes. On the other hand, midurethral slings are not all the same. It is important to appreciate the more subtle differences, to be aware of the evidence, and to be appropriately trained. Often, sling selection involves weighing the risks and benefits for the individual.

On a broad scale, the most recent high-level comparison of the retropubic and transobturator slings appears to be a meta-analysis in which retropubic midurethral slings showed better objective and subjective cure rates than transobturator midurethral slings. Women treated with retropubic slings had a 35% higher odds of objective cure and a 24% higher odds of subjective cure. (The weighted average objective cure rates were 87% for retropubic slings vs. 83% for transobturator slings with a weighted average follow-up of approximately 17 months. The weighted average subjective cure rates were 76% and 73%, respectively.)

Operating times were longer with retropubic slings, but lengths of stay were equivalent between the two types of procedures. This was based on 17 studies of about 3,000 women (J. Urology 2014 [doi: 10.1016/j.juro.2014.09.104]).

The types of complications seen with each approach differed. Bladder perforation was significantly more common with retropubic slings (3.2% vs. 0.2%), as was bleeding (3.2% v. 1.1%). Transobturator slings were associated with more cases of neurologic symptoms (9.4% v. 3.5%) and vaginal perforation (3.6% v. 0.9%).

This new review provides updated information to the 2009 Cochrane Review mentioned above, which reported that women were less likely to be continent after operations performed via the obturator route, but also less likely to have encountered complications. More specifically, objective cure rates were slightly higher with retropubic slings than with transobturator slings (88% vs. 84%) in the 2009 review. There was no difference in subjective cure rates. With the obturator route, there was less voiding dysfunction, blood loss, and bladder perforation (0.3% v. 5.5%).

Other pivotal trials since the 2009 Cochrane Review include a multicenter randomized equivalence trial published in the New England Journal of Medicine in 2010. The trial randomized 597 women to transobturator or retropubic sling surgery, and found no significant differences in subjective success (56% vs. 62%) or in objective success (78% vs. 81%) at 12 months (N. Engl. J. Med. 2010;362:2066-76).

There is some level 1 evidence suggesting that for severe incontinence involving intrinsic sphincter deficiency (ISD), a retropubic TVT sling is the more effective procedure. A randomized trial of 164 women with urodynamic SUI and ISD, for instance, found that 21% of those in the TVT group and 45% of those in the transobturator group had urodynamic SUI 6 months postoperatively.

The risk ratio of repeat surgery was 2.6 times higher in the transobturator group than in the retropubic TVT group (Obstet. Gynecol. 2008;112:1253-61). TVT was more effective both with and without concurrent pelvic organ prolapse repair.

I tell my patients with severe SUI or ISD, therefore, that retropubic sling procedures appear to be preferable. (Exceptions include the patient who has a history of retropubic surgeries, in whom passing the sling through this route may not be the safest approach, as well as the patient who has had mesh erosion into the bladder.)

In patients whose SUI is less severe, I counsel that a transobturator sling confers satisfaction rates similar to those of a retropubic sling and has a lower risk of complications, such as postoperative voiding dysfunction and bladder perforations, but with the possible trade-off of more thigh discomfort. I also might recommend a transobturator sling to patients with more pronounced initial complaints of urinary urgency and frequency, and to patients who have minor voiding dysfunction or a low level of incomplete bladder emptying.

 

 

While often short-lived, the small risk of thigh pain with a transobturator sling makes me less likely to recommend this type of sling for a woman who is a marathon runner or competitive athlete. In her case, an analysis of possible complications includes the consideration that bladder perforation can be addressed relatively quickly in the operating room, while persistent thigh discomfort, though relatively rare, could be a debilitating problem.

Single-incision slings

There appears to be emerging evidence suggesting that some of the fixed and adjustable single-incision slings currently available may have efficacy similar to that of the slings that are now widely used.

A Cochrane Review presented at the 2014 AUGS-IUGA scientific meeting and published this summer concludes that there is not enough evidence on single-incision slings compared with retropubic or transobturator slings to allow reliable comparisons, and that additional, adequately powered, high-quality trials with longer-term follow-up are needed (Cochrane Database Sys. Rev. 2014;6:CD008709). However, research completed since the review offers additional data.

For instance, at the 2014 AUGS-IUGA scientific meeting this summer, an oral paper presentation highlighted findings of a randomized controlled trial that showed similar cure rates after surgery with the MiniArc, a fixed single-incision sling, and the Monarc transobturator sling (both by American Medical Systems) at 24 months. The study randomized 234 women to either sling and found no significant differences in subjective outcomes, objective outcomes, or results on various quality-of-life questionnaires.

As such studies are published and more evidence emerges, we will gain a clearer picture of how the newer single-incision slings compare to the well-tested retropubic and transobturator slings with respect to efficacy and safety.

Single-incision slings require only a small vaginal incision and no exit points. Without abdominal or thigh incisions, these new procedures – intended for less severe SUI (no ISD) – may offer improved perioperative and postoperative patient comfort and a potentially decreased risk of surgical injury to the adductor muscles, as well as a decreased risk of vascular and nerve injury. Candidates for these slings may include those who are very athletic, those who are obese, and those with a history of prior retropubic or pelvic surgery.

Research appears to be progressing, but at this time we do not yet have level 1 evidence to support their routine use.

Dr. Sokol reported that he owns stock in Pelvalon, and is a clinical adviser to that company. He also is a national principal investigator for American Medical Systems, and the recipient of research grants from Acell and several other companies.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Midurethral slings
Display Headline
Midurethral slings
Legacy Keywords
midurethral slings, tranobturator, retropublic, stress urinary incontinence
Legacy Keywords
midurethral slings, tranobturator, retropublic, stress urinary incontinence
Sections
Article Source

PURLs Copyright

Inside the Article

Treatment of stress urinary incontinence

Article Type
Changed
Display Headline
Treatment of stress urinary incontinence

According to a 2004 article by Dr. Eric S. Rovner and Dr. Alan J. Wein, 200 different surgical procedures have been described to treat stress urinary incontinence (Rev. Urol. 2004;6(Suppl 3):S29-47). Two goals exist in such surgical procedures:

1. Urethra repositioning or stabilization of the urethra and bladder neck through creation of retropubic support that is impervious to intraabdominal pressure changes.

2. Augmentation of the ureteral resistance provided by the intrinsic sphincter unit, with or without impacting urethra and bladder neck support (sling vs. periurethral injectables, or a combination of the two).

Dr. Charles E. Miller

Sling procedures were initially introduced almost a century ago and have recently become increasingly popular – in part, secondary to a decrease in associated morbidity. Unlike transabdominal or transvaginal urethropexy, a sling not only provides support to the vesicourethral junction, but also may create some aspect of urethral coaptation or compression.

Midurethral slings were introduced nearly 20 years ago. These procedures can be performed with a local anesthetic or with minimal regional anesthesia – thus, in an outpatient setting. In addition, midurethral slings are associated with decreased pain and postoperative convalescence.

I have asked Dr. Eric Russell Sokol to lead this state-of-the-art discussion on midurethral slings. Dr. Sokol is an associate professor of obstetrics and gynecology, associate professor of urology (by courtesy), and cochief of the division of urogynecology and pelvic reconstructive surgery at Stanford (Calif.) University. He has published many articles regarding urogynecology and minimally invasive surgery. Dr. Sokol has been awarded numerous teaching awards, and he is a reviewer for multiple prestigious, peer-reviewed journals. It is a pleasure and an honor to welcome Dr. Sokol to this edition of Master Class in Gynecologic Surgery, the second installment on urinary incontinence.

Dr. Miller is clinical associate professor at the University of Illinois at Chicago, immediate past president of the International Society for Gynecologic Endoscopy (ISGE), and a past president of the AAGL. He is a reproductive endocrinologist and minimally invasive gynecologic surgeon in private practice in Naperville, Ill., and Schaumburg, Ill.; the director of minimally invasive gynecologic surgery and the director of the AAGL/SRS fellowship in minimally invasive gynecologic surgery at Advocate Lutheran General Hospital, Park Ridge, Ill.; and the medical editor of this column, Master Class. Dr. Miller is a consultant and on the speaker’s bureau for Ethicon.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
stress urinary incontinence, midurethral slings, urogynecology
Sections
Author and Disclosure Information

Author and Disclosure Information

According to a 2004 article by Dr. Eric S. Rovner and Dr. Alan J. Wein, 200 different surgical procedures have been described to treat stress urinary incontinence (Rev. Urol. 2004;6(Suppl 3):S29-47). Two goals exist in such surgical procedures:

1. Urethra repositioning or stabilization of the urethra and bladder neck through creation of retropubic support that is impervious to intraabdominal pressure changes.

2. Augmentation of the ureteral resistance provided by the intrinsic sphincter unit, with or without impacting urethra and bladder neck support (sling vs. periurethral injectables, or a combination of the two).

Dr. Charles E. Miller

Sling procedures were initially introduced almost a century ago and have recently become increasingly popular – in part, secondary to a decrease in associated morbidity. Unlike transabdominal or transvaginal urethropexy, a sling not only provides support to the vesicourethral junction, but also may create some aspect of urethral coaptation or compression.

Midurethral slings were introduced nearly 20 years ago. These procedures can be performed with a local anesthetic or with minimal regional anesthesia – thus, in an outpatient setting. In addition, midurethral slings are associated with decreased pain and postoperative convalescence.

I have asked Dr. Eric Russell Sokol to lead this state-of-the-art discussion on midurethral slings. Dr. Sokol is an associate professor of obstetrics and gynecology, associate professor of urology (by courtesy), and cochief of the division of urogynecology and pelvic reconstructive surgery at Stanford (Calif.) University. He has published many articles regarding urogynecology and minimally invasive surgery. Dr. Sokol has been awarded numerous teaching awards, and he is a reviewer for multiple prestigious, peer-reviewed journals. It is a pleasure and an honor to welcome Dr. Sokol to this edition of Master Class in Gynecologic Surgery, the second installment on urinary incontinence.

Dr. Miller is clinical associate professor at the University of Illinois at Chicago, immediate past president of the International Society for Gynecologic Endoscopy (ISGE), and a past president of the AAGL. He is a reproductive endocrinologist and minimally invasive gynecologic surgeon in private practice in Naperville, Ill., and Schaumburg, Ill.; the director of minimally invasive gynecologic surgery and the director of the AAGL/SRS fellowship in minimally invasive gynecologic surgery at Advocate Lutheran General Hospital, Park Ridge, Ill.; and the medical editor of this column, Master Class. Dr. Miller is a consultant and on the speaker’s bureau for Ethicon.

According to a 2004 article by Dr. Eric S. Rovner and Dr. Alan J. Wein, 200 different surgical procedures have been described to treat stress urinary incontinence (Rev. Urol. 2004;6(Suppl 3):S29-47). Two goals exist in such surgical procedures:

1. Urethra repositioning or stabilization of the urethra and bladder neck through creation of retropubic support that is impervious to intraabdominal pressure changes.

2. Augmentation of the ureteral resistance provided by the intrinsic sphincter unit, with or without impacting urethra and bladder neck support (sling vs. periurethral injectables, or a combination of the two).

Dr. Charles E. Miller

Sling procedures were initially introduced almost a century ago and have recently become increasingly popular – in part, secondary to a decrease in associated morbidity. Unlike transabdominal or transvaginal urethropexy, a sling not only provides support to the vesicourethral junction, but also may create some aspect of urethral coaptation or compression.

Midurethral slings were introduced nearly 20 years ago. These procedures can be performed with a local anesthetic or with minimal regional anesthesia – thus, in an outpatient setting. In addition, midurethral slings are associated with decreased pain and postoperative convalescence.

I have asked Dr. Eric Russell Sokol to lead this state-of-the-art discussion on midurethral slings. Dr. Sokol is an associate professor of obstetrics and gynecology, associate professor of urology (by courtesy), and cochief of the division of urogynecology and pelvic reconstructive surgery at Stanford (Calif.) University. He has published many articles regarding urogynecology and minimally invasive surgery. Dr. Sokol has been awarded numerous teaching awards, and he is a reviewer for multiple prestigious, peer-reviewed journals. It is a pleasure and an honor to welcome Dr. Sokol to this edition of Master Class in Gynecologic Surgery, the second installment on urinary incontinence.

Dr. Miller is clinical associate professor at the University of Illinois at Chicago, immediate past president of the International Society for Gynecologic Endoscopy (ISGE), and a past president of the AAGL. He is a reproductive endocrinologist and minimally invasive gynecologic surgeon in private practice in Naperville, Ill., and Schaumburg, Ill.; the director of minimally invasive gynecologic surgery and the director of the AAGL/SRS fellowship in minimally invasive gynecologic surgery at Advocate Lutheran General Hospital, Park Ridge, Ill.; and the medical editor of this column, Master Class. Dr. Miller is a consultant and on the speaker’s bureau for Ethicon.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Treatment of stress urinary incontinence
Display Headline
Treatment of stress urinary incontinence
Legacy Keywords
stress urinary incontinence, midurethral slings, urogynecology
Legacy Keywords
stress urinary incontinence, midurethral slings, urogynecology
Sections
Article Source

PURLs Copyright

Inside the Article

Commentary: Depressive realism and Ferguson

Article Type
Changed
Display Headline
Commentary: Depressive realism and Ferguson

At some point in medical school, you might have come across the psychological theory of depressive realism, developed by Lauren Alloy, Ph.D., and Lyn Yvonne Abramson, Ph.D. The theory challenges traditional views of depression and suggests that an individual can become so entrenched in the reality of his status that it becomes overwhelmingly sad-depressive. This theory overturns the traditional view that nondepressed individuals are normal.

What happens when a large mass of individuals stops the delusion of their safe reality and dares to face, head on, their actual reality? Denying themselves rose-colored glasses? The answer is the birth of an entire community of people who dare to change the structure that ensures their depression is real. The product of this new birth are warriors, brave, intellectual, fearless activists who stand with mirrors to our societal made-up face with one hand, while snatching away the rose-tinted glasses with the other. Activists have made some uncomfortable because of the seed planted in the belly of their consciousness: an undeniable urge to do something. It makes us uncomfortable because we know that a national tragedy of this magnitude makes the need for psychiatric and psychological services undeniable and begs us each to answer the question: “What am I doing?”

Dr. Marva M. Robinson

As the current president for the St. Louis Association of Black Psychologists (STL ABPsi), I have seen face-to-face the devastation of what happens to a region plagued by depression, trauma, and generalized anxiety for 100 days with little to no focus on mental health. Regardless of your opinion of what occurred Aug. 9 between Michael “Mike Mike” Brown and Officer Darren Wilson of Ferguson, Mo., what we each should have an opinion of is the need to address the mental health of a community that has been forever changed following the interaction of those two individuals.

As of this writing, St. Louis County prosecuting attorney Robert McCullough has announced that the grand jury tasked with looking at all of the evidence in the case has decided not to indict Officer Wilson, and we are awaiting the results of the U.S. Justice Department investigation. The community is responding to the no indictment announcement in ways described by the St. Louis Post-Dispatch as "much worse than August."

As mental health providers, we must not wait for what happens next. We must be concerned right now that children are having nightmares; some parents are so hypervigilant that any dropped objects are striking a startle response; and many of our young boys and girls are walking in fear of seeing militarized police officers jump out of bushes.

When STL ABPsi entered the Canfield Apartment Complex, now referred to (by residents) as “ground zero,” we were unsure of what to expect. We simply understood that a community was grieving, and entire families were devastated by witnessing one of their community members lying in the street, face down, in his own blood, littered with bullets for more than 4 hours. Detailed visions of what they saw were at the start of every conversation for weeks and months to come.

As we provided crisis intervention services, we listened to parents with concern about their potty-trained children wetting the bed. Fathers disclosed feeling a sense of numbness. Mothers discussed their frustration with poor concentration, their own nightmares, and numbness. This might sound like a description of a war zone in a third-world country, but I am sad to report these are the symptoms suffered by American citizens not only in Ferguson but in other parts of the St. Louis metropolitan area.

It is my hope that behavioral health providers across the country also will be moved to do something to address the pain that plagues our region. Psychiatrists nationwide can choose to stand on the right side of history by supporting a local organization, volunteering medical services, or making a donation to organizations focused on supporting the mental health needs of St. Louis. It is my hope that the profession I have chosen to make my career is not left out of the recorded history of this historic moment. While many will agree, the time for justice is always right now. I urge my psychiatric community to boldly stand in our truth, that the movement for healing our children and families is certainly right now. What will you do?

Dr. Robinson is a licensed clinical psychologist in private practice in St. Louis.

References

Author and Disclosure Information

Publications
Legacy Keywords
Ferguson, Mike Brown, Officer Darren Wilson
Sections
Author and Disclosure Information

Author and Disclosure Information

At some point in medical school, you might have come across the psychological theory of depressive realism, developed by Lauren Alloy, Ph.D., and Lyn Yvonne Abramson, Ph.D. The theory challenges traditional views of depression and suggests that an individual can become so entrenched in the reality of his status that it becomes overwhelmingly sad-depressive. This theory overturns the traditional view that nondepressed individuals are normal.

What happens when a large mass of individuals stops the delusion of their safe reality and dares to face, head on, their actual reality? Denying themselves rose-colored glasses? The answer is the birth of an entire community of people who dare to change the structure that ensures their depression is real. The product of this new birth are warriors, brave, intellectual, fearless activists who stand with mirrors to our societal made-up face with one hand, while snatching away the rose-tinted glasses with the other. Activists have made some uncomfortable because of the seed planted in the belly of their consciousness: an undeniable urge to do something. It makes us uncomfortable because we know that a national tragedy of this magnitude makes the need for psychiatric and psychological services undeniable and begs us each to answer the question: “What am I doing?”

Dr. Marva M. Robinson

As the current president for the St. Louis Association of Black Psychologists (STL ABPsi), I have seen face-to-face the devastation of what happens to a region plagued by depression, trauma, and generalized anxiety for 100 days with little to no focus on mental health. Regardless of your opinion of what occurred Aug. 9 between Michael “Mike Mike” Brown and Officer Darren Wilson of Ferguson, Mo., what we each should have an opinion of is the need to address the mental health of a community that has been forever changed following the interaction of those two individuals.

As of this writing, St. Louis County prosecuting attorney Robert McCullough has announced that the grand jury tasked with looking at all of the evidence in the case has decided not to indict Officer Wilson, and we are awaiting the results of the U.S. Justice Department investigation. The community is responding to the no indictment announcement in ways described by the St. Louis Post-Dispatch as "much worse than August."

As mental health providers, we must not wait for what happens next. We must be concerned right now that children are having nightmares; some parents are so hypervigilant that any dropped objects are striking a startle response; and many of our young boys and girls are walking in fear of seeing militarized police officers jump out of bushes.

When STL ABPsi entered the Canfield Apartment Complex, now referred to (by residents) as “ground zero,” we were unsure of what to expect. We simply understood that a community was grieving, and entire families were devastated by witnessing one of their community members lying in the street, face down, in his own blood, littered with bullets for more than 4 hours. Detailed visions of what they saw were at the start of every conversation for weeks and months to come.

As we provided crisis intervention services, we listened to parents with concern about their potty-trained children wetting the bed. Fathers disclosed feeling a sense of numbness. Mothers discussed their frustration with poor concentration, their own nightmares, and numbness. This might sound like a description of a war zone in a third-world country, but I am sad to report these are the symptoms suffered by American citizens not only in Ferguson but in other parts of the St. Louis metropolitan area.

It is my hope that behavioral health providers across the country also will be moved to do something to address the pain that plagues our region. Psychiatrists nationwide can choose to stand on the right side of history by supporting a local organization, volunteering medical services, or making a donation to organizations focused on supporting the mental health needs of St. Louis. It is my hope that the profession I have chosen to make my career is not left out of the recorded history of this historic moment. While many will agree, the time for justice is always right now. I urge my psychiatric community to boldly stand in our truth, that the movement for healing our children and families is certainly right now. What will you do?

Dr. Robinson is a licensed clinical psychologist in private practice in St. Louis.

At some point in medical school, you might have come across the psychological theory of depressive realism, developed by Lauren Alloy, Ph.D., and Lyn Yvonne Abramson, Ph.D. The theory challenges traditional views of depression and suggests that an individual can become so entrenched in the reality of his status that it becomes overwhelmingly sad-depressive. This theory overturns the traditional view that nondepressed individuals are normal.

What happens when a large mass of individuals stops the delusion of their safe reality and dares to face, head on, their actual reality? Denying themselves rose-colored glasses? The answer is the birth of an entire community of people who dare to change the structure that ensures their depression is real. The product of this new birth are warriors, brave, intellectual, fearless activists who stand with mirrors to our societal made-up face with one hand, while snatching away the rose-tinted glasses with the other. Activists have made some uncomfortable because of the seed planted in the belly of their consciousness: an undeniable urge to do something. It makes us uncomfortable because we know that a national tragedy of this magnitude makes the need for psychiatric and psychological services undeniable and begs us each to answer the question: “What am I doing?”

Dr. Marva M. Robinson

As the current president for the St. Louis Association of Black Psychologists (STL ABPsi), I have seen face-to-face the devastation of what happens to a region plagued by depression, trauma, and generalized anxiety for 100 days with little to no focus on mental health. Regardless of your opinion of what occurred Aug. 9 between Michael “Mike Mike” Brown and Officer Darren Wilson of Ferguson, Mo., what we each should have an opinion of is the need to address the mental health of a community that has been forever changed following the interaction of those two individuals.

As of this writing, St. Louis County prosecuting attorney Robert McCullough has announced that the grand jury tasked with looking at all of the evidence in the case has decided not to indict Officer Wilson, and we are awaiting the results of the U.S. Justice Department investigation. The community is responding to the no indictment announcement in ways described by the St. Louis Post-Dispatch as "much worse than August."

As mental health providers, we must not wait for what happens next. We must be concerned right now that children are having nightmares; some parents are so hypervigilant that any dropped objects are striking a startle response; and many of our young boys and girls are walking in fear of seeing militarized police officers jump out of bushes.

When STL ABPsi entered the Canfield Apartment Complex, now referred to (by residents) as “ground zero,” we were unsure of what to expect. We simply understood that a community was grieving, and entire families were devastated by witnessing one of their community members lying in the street, face down, in his own blood, littered with bullets for more than 4 hours. Detailed visions of what they saw were at the start of every conversation for weeks and months to come.

As we provided crisis intervention services, we listened to parents with concern about their potty-trained children wetting the bed. Fathers disclosed feeling a sense of numbness. Mothers discussed their frustration with poor concentration, their own nightmares, and numbness. This might sound like a description of a war zone in a third-world country, but I am sad to report these are the symptoms suffered by American citizens not only in Ferguson but in other parts of the St. Louis metropolitan area.

It is my hope that behavioral health providers across the country also will be moved to do something to address the pain that plagues our region. Psychiatrists nationwide can choose to stand on the right side of history by supporting a local organization, volunteering medical services, or making a donation to organizations focused on supporting the mental health needs of St. Louis. It is my hope that the profession I have chosen to make my career is not left out of the recorded history of this historic moment. While many will agree, the time for justice is always right now. I urge my psychiatric community to boldly stand in our truth, that the movement for healing our children and families is certainly right now. What will you do?

Dr. Robinson is a licensed clinical psychologist in private practice in St. Louis.

References

References

Publications
Publications
Article Type
Display Headline
Commentary: Depressive realism and Ferguson
Display Headline
Commentary: Depressive realism and Ferguson
Legacy Keywords
Ferguson, Mike Brown, Officer Darren Wilson
Legacy Keywords
Ferguson, Mike Brown, Officer Darren Wilson
Sections
Article Source

PURLs Copyright

Inside the Article

Commentary: The value of the doctor-patient relationship

Article Type
Changed
Display Headline
Commentary: The value of the doctor-patient relationship

My computer flashes a message that Lisa checked in, so I go to the waiting area of the college counseling center where I work. At first I do not see her, but then I notice a short, thin woman sitting in the corner, her head bowed with long, wavy blond hair covering her face.

Lisa came in for an appointment at the beginning of the semester and then missed the next appointment. After a few e-mails and phone calls on my part, I get her in for a follow-up visit. I do not always pursue a patient, but I am worried about Lisa. She was hospitalized a few months earlier after becoming paranoid and hitting her mother.

Dr. Marcia Morris

We walk into my office, and she sits and looks at me, pushing her hair from her face so I can see her blue eyes. She starts by telling me: “I ran out of medication, but I know I need to restart it.” I ask her to tell me how she knows.

“Since I stopped taking medication, my friends are getting annoyed with me for talking too much and keeping them awake when I call late at night. My professor spoke with me after class and told me I was being disruptive with all my questions. I think I am too revved up, and it is getting hard to concentrate on my school work.”

I feel a deep sense of relief that Lisa has insight into how her behavior affects others and that medication can help her. This is a major step for her, and I am hopeful that she will continue treatment that helps her achieve her goals. I praise Lisa for listening to feedback from others.

Lisa’s insight has been limited in the past. Her first hospitalization was 1 year ago, her second 2 months ago, both for psychotic episodes following escalating marijuana use. She had been a regular cannabis smoker since coming to college. Did the marijuana cause psychosis, or did she increase use to self-medicate psychosis? This will be debated until the end of time, but I don’t believe marijuana benefits her. She has been in college for 7 years.

I started to see Lisa after her first hospitalization. I was relieved that she subsequently stopped using marijuana and took an antipsychotic. Her mind cleared, and she successfully completed the semester. After 4 months of treatment, she told me she was going to taper her medication and would not need to see me anymore. I was sad, but not surprised, when she returned to my care after the second hospitalization.

Lisa still doubts she has bipolar disorder, a diagnosis she was given in the hospital. Whatever her diagnosis is, I ask her to consider using antipsychotic medication as a tool, along with therapy, friendship, exercise, and healthy eating, to accomplish her goal, graduating from college, which she will do at the end of the semester.

With Lisa, I see more trust with each visit. I also see a rocky road ahead for her, as she still uses marijuana, although not on a daily basis. I have tried to convince her of the benefits of abstinence, without success. I believe the antipsychotic is helping her, so I prescribe it. I schedule a follow-up appointment.

Sitting with patients like Lisa, believing you are slowly making steps toward wellness, is deeply rewarding. My job in a college counseling center allows me to spend 30-45 minutes in follow-up with my patients and meet as often as I need to. Lisa would be lucky in the public health sector to see someone every 3 months for 15 minutes.

I truly feel we as college mental health psychiatrists are often in the role of in loco parentis, and we make a difference. The doctor-patient relationship is the key element in our treatment, enabling patients to trust our recommendations, whether it is for medication, therapy, or exercise. Sometimes, with patients like Lisa, the trust has to be built up over time.

The importance of the doctor-patient relationship has not changed in the last 21 years since I completed my training. Sometimes, it is a battle to maintain this relationship, as I spend an increasing amount of time bent over my computer typing and tapping information into the electronic medical record. My notes have gone from short stories to novellas, as I fill in information to meet insurance, risk management, and psychiatry board requirements. I fear I will soon have a closer relationship with my computer than with my patients. Sometimes I feel like the astronaut in “2001: A Space Odyssey,” and Hal the computer has taken over my life.

 

 

Patients like Lisa literally bring me down to earth and help me remember why I became a psychiatrist. As I puzzle over how to strengthen the doctor-patient bond, I try to plant the seeds that will allow Lisa to forego marijuana and other drugs for good. I encourage her to connect with others in her shoes by going to a support group, acknowledging my own deficits in knowing her experience but my desire to understand it as best I can. The connections I form with patients, especially the more challenging ones like Lisa, cannot be measured, and don’t have a reimbursement code, but they are priceless.

Dr. Morris is a psychiatrist at the University of Florida Counseling and Wellness Center in Gainesville and has provided clinical care to University of Florida students for the last 20 years. Her areas of specialty include depression, eating disorders, and anxiety disorders.

References

Author and Disclosure Information

Publications
Legacy Keywords
doctor-patient relationship, cannabis, college counseling center
Sections
Author and Disclosure Information

Author and Disclosure Information

My computer flashes a message that Lisa checked in, so I go to the waiting area of the college counseling center where I work. At first I do not see her, but then I notice a short, thin woman sitting in the corner, her head bowed with long, wavy blond hair covering her face.

Lisa came in for an appointment at the beginning of the semester and then missed the next appointment. After a few e-mails and phone calls on my part, I get her in for a follow-up visit. I do not always pursue a patient, but I am worried about Lisa. She was hospitalized a few months earlier after becoming paranoid and hitting her mother.

Dr. Marcia Morris

We walk into my office, and she sits and looks at me, pushing her hair from her face so I can see her blue eyes. She starts by telling me: “I ran out of medication, but I know I need to restart it.” I ask her to tell me how she knows.

“Since I stopped taking medication, my friends are getting annoyed with me for talking too much and keeping them awake when I call late at night. My professor spoke with me after class and told me I was being disruptive with all my questions. I think I am too revved up, and it is getting hard to concentrate on my school work.”

I feel a deep sense of relief that Lisa has insight into how her behavior affects others and that medication can help her. This is a major step for her, and I am hopeful that she will continue treatment that helps her achieve her goals. I praise Lisa for listening to feedback from others.

Lisa’s insight has been limited in the past. Her first hospitalization was 1 year ago, her second 2 months ago, both for psychotic episodes following escalating marijuana use. She had been a regular cannabis smoker since coming to college. Did the marijuana cause psychosis, or did she increase use to self-medicate psychosis? This will be debated until the end of time, but I don’t believe marijuana benefits her. She has been in college for 7 years.

I started to see Lisa after her first hospitalization. I was relieved that she subsequently stopped using marijuana and took an antipsychotic. Her mind cleared, and she successfully completed the semester. After 4 months of treatment, she told me she was going to taper her medication and would not need to see me anymore. I was sad, but not surprised, when she returned to my care after the second hospitalization.

Lisa still doubts she has bipolar disorder, a diagnosis she was given in the hospital. Whatever her diagnosis is, I ask her to consider using antipsychotic medication as a tool, along with therapy, friendship, exercise, and healthy eating, to accomplish her goal, graduating from college, which she will do at the end of the semester.

With Lisa, I see more trust with each visit. I also see a rocky road ahead for her, as she still uses marijuana, although not on a daily basis. I have tried to convince her of the benefits of abstinence, without success. I believe the antipsychotic is helping her, so I prescribe it. I schedule a follow-up appointment.

Sitting with patients like Lisa, believing you are slowly making steps toward wellness, is deeply rewarding. My job in a college counseling center allows me to spend 30-45 minutes in follow-up with my patients and meet as often as I need to. Lisa would be lucky in the public health sector to see someone every 3 months for 15 minutes.

I truly feel we as college mental health psychiatrists are often in the role of in loco parentis, and we make a difference. The doctor-patient relationship is the key element in our treatment, enabling patients to trust our recommendations, whether it is for medication, therapy, or exercise. Sometimes, with patients like Lisa, the trust has to be built up over time.

The importance of the doctor-patient relationship has not changed in the last 21 years since I completed my training. Sometimes, it is a battle to maintain this relationship, as I spend an increasing amount of time bent over my computer typing and tapping information into the electronic medical record. My notes have gone from short stories to novellas, as I fill in information to meet insurance, risk management, and psychiatry board requirements. I fear I will soon have a closer relationship with my computer than with my patients. Sometimes I feel like the astronaut in “2001: A Space Odyssey,” and Hal the computer has taken over my life.

 

 

Patients like Lisa literally bring me down to earth and help me remember why I became a psychiatrist. As I puzzle over how to strengthen the doctor-patient bond, I try to plant the seeds that will allow Lisa to forego marijuana and other drugs for good. I encourage her to connect with others in her shoes by going to a support group, acknowledging my own deficits in knowing her experience but my desire to understand it as best I can. The connections I form with patients, especially the more challenging ones like Lisa, cannot be measured, and don’t have a reimbursement code, but they are priceless.

Dr. Morris is a psychiatrist at the University of Florida Counseling and Wellness Center in Gainesville and has provided clinical care to University of Florida students for the last 20 years. Her areas of specialty include depression, eating disorders, and anxiety disorders.

My computer flashes a message that Lisa checked in, so I go to the waiting area of the college counseling center where I work. At first I do not see her, but then I notice a short, thin woman sitting in the corner, her head bowed with long, wavy blond hair covering her face.

Lisa came in for an appointment at the beginning of the semester and then missed the next appointment. After a few e-mails and phone calls on my part, I get her in for a follow-up visit. I do not always pursue a patient, but I am worried about Lisa. She was hospitalized a few months earlier after becoming paranoid and hitting her mother.

Dr. Marcia Morris

We walk into my office, and she sits and looks at me, pushing her hair from her face so I can see her blue eyes. She starts by telling me: “I ran out of medication, but I know I need to restart it.” I ask her to tell me how she knows.

“Since I stopped taking medication, my friends are getting annoyed with me for talking too much and keeping them awake when I call late at night. My professor spoke with me after class and told me I was being disruptive with all my questions. I think I am too revved up, and it is getting hard to concentrate on my school work.”

I feel a deep sense of relief that Lisa has insight into how her behavior affects others and that medication can help her. This is a major step for her, and I am hopeful that she will continue treatment that helps her achieve her goals. I praise Lisa for listening to feedback from others.

Lisa’s insight has been limited in the past. Her first hospitalization was 1 year ago, her second 2 months ago, both for psychotic episodes following escalating marijuana use. She had been a regular cannabis smoker since coming to college. Did the marijuana cause psychosis, or did she increase use to self-medicate psychosis? This will be debated until the end of time, but I don’t believe marijuana benefits her. She has been in college for 7 years.

I started to see Lisa after her first hospitalization. I was relieved that she subsequently stopped using marijuana and took an antipsychotic. Her mind cleared, and she successfully completed the semester. After 4 months of treatment, she told me she was going to taper her medication and would not need to see me anymore. I was sad, but not surprised, when she returned to my care after the second hospitalization.

Lisa still doubts she has bipolar disorder, a diagnosis she was given in the hospital. Whatever her diagnosis is, I ask her to consider using antipsychotic medication as a tool, along with therapy, friendship, exercise, and healthy eating, to accomplish her goal, graduating from college, which she will do at the end of the semester.

With Lisa, I see more trust with each visit. I also see a rocky road ahead for her, as she still uses marijuana, although not on a daily basis. I have tried to convince her of the benefits of abstinence, without success. I believe the antipsychotic is helping her, so I prescribe it. I schedule a follow-up appointment.

Sitting with patients like Lisa, believing you are slowly making steps toward wellness, is deeply rewarding. My job in a college counseling center allows me to spend 30-45 minutes in follow-up with my patients and meet as often as I need to. Lisa would be lucky in the public health sector to see someone every 3 months for 15 minutes.

I truly feel we as college mental health psychiatrists are often in the role of in loco parentis, and we make a difference. The doctor-patient relationship is the key element in our treatment, enabling patients to trust our recommendations, whether it is for medication, therapy, or exercise. Sometimes, with patients like Lisa, the trust has to be built up over time.

The importance of the doctor-patient relationship has not changed in the last 21 years since I completed my training. Sometimes, it is a battle to maintain this relationship, as I spend an increasing amount of time bent over my computer typing and tapping information into the electronic medical record. My notes have gone from short stories to novellas, as I fill in information to meet insurance, risk management, and psychiatry board requirements. I fear I will soon have a closer relationship with my computer than with my patients. Sometimes I feel like the astronaut in “2001: A Space Odyssey,” and Hal the computer has taken over my life.

 

 

Patients like Lisa literally bring me down to earth and help me remember why I became a psychiatrist. As I puzzle over how to strengthen the doctor-patient bond, I try to plant the seeds that will allow Lisa to forego marijuana and other drugs for good. I encourage her to connect with others in her shoes by going to a support group, acknowledging my own deficits in knowing her experience but my desire to understand it as best I can. The connections I form with patients, especially the more challenging ones like Lisa, cannot be measured, and don’t have a reimbursement code, but they are priceless.

Dr. Morris is a psychiatrist at the University of Florida Counseling and Wellness Center in Gainesville and has provided clinical care to University of Florida students for the last 20 years. Her areas of specialty include depression, eating disorders, and anxiety disorders.

References

References

Publications
Publications
Article Type
Display Headline
Commentary: The value of the doctor-patient relationship
Display Headline
Commentary: The value of the doctor-patient relationship
Legacy Keywords
doctor-patient relationship, cannabis, college counseling center
Legacy Keywords
doctor-patient relationship, cannabis, college counseling center
Sections
Article Source

PURLs Copyright

Inside the Article

CLINICAL GUIDELINES: Primary care bronchiolitis guidelines

Article Type
Changed
Display Headline
CLINICAL GUIDELINES: Primary care bronchiolitis guidelines

Bronchiolitis is the most common cause of hospitalization among infants during the first 12 months of life. Approximately 100,000 bronchiolitis admissions occur annually in children in the United States, at an estimated cost of $1.73 billion. The American Academy of Pediatrics recently published new guidelines for the diagnosis, management, and prevention of bronchiolitis in children younger than 2 years.

Dr. Neil Skolnik and Dr. Neha Rastogi

Diagnosis

Diagnosis is based on patient history and physical examination. The course and severity of bronchiolitis vary, ranging from mild disease with simple runny nose and cough, to transient apneic events, and on to progressive respiratory distress secondary to airway obstruction. Management of bronchiolitis must be determined in the context of increased risk factors for severe disease, including age less than 12 weeks, history of prematurity, underlying cardiopulmonary disease, and immunodeficiency. Current evidence does not support routine labs or diagnostic imaging as helping with risk assessment. Abnormalities on chest x-ray, which are common in children with bronchiolitis, do reliably predict severity of disease, so chest x-rays are only indicated when another etiology of respiratory distress such as pneumothorax or pneumonia is a concern. Routine virologic testing is not recommended, as it does not appear to aid in guiding the treatment of the child with bronchiolitis.

Management

Randomized trials have not shown any benefit from alpha- or beta-adrenergic agonist administration. Bronchodilators can lessen symptoms scores, but their use does not speed disease resolution or decrease the length of stay or need for hospitalization. A Cochrane analysis concluded that there was no benefit to giving bronchodilators to infants with bronchiolitis. Adverse effects included tachycardia, tremors, and cost, all of which outweigh potential benefits. While previous versions of the AAP guidelines recommended bronchodilators as an option, the 2014 guidelines state, “Clinicians should not administer albuterol (or salbutamol) to infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Strong).” It is noted that there may be some children who have reversible airway obstruction, but it is impossible to tell ahead of time who they are; and due to the variability of the disease, it is even hard to tell in whom the medication is effective. It is acknowledged that children with severe disease were usually excluded from the studies of bronchodilators. Epinephrine should also not be used except potentially as a rescue agent in severe disease.

Nebulized hypertonic saline appears to increase mucociliary clearance. Nebulized 3% saline is safe and effective in improving symptoms of mild to moderate bronchiolitis when measured after 24 hours of use, and it possibly decreases the length of hospital stay in studies where the length of stay exceeded 3 days. The guidelines conclude that hypertonic saline may be helpful to infants who are hospitalized with bronchiolitis, but probably is of very little benefit when administered in an emergency department setting.

Although there is strong evidence of benefit of systemic corticosteroids in asthma and croup, there is no evidence that systemic corticosteroids provide benefit in bronchiolitis. In addition, there is some evidence that corticosteroids may prolong viral shedding. For these reasons, the 2014 guidelines state, “Clinicians should not administer systemic corticosteroids to infants with a diagnosis of bronchiolitis in any setting (Evidence Quality: A; Recommendation Strength: Strong Recommendation).”

Physicians may choose not to give supplemental oxygen if oxyhemoglobin saturation is more than 90%, and also not to use continuous pulse oximetry given that it is prone to errors of measurement. Chest physiotherapy is not recommended. Antibiotics use is not recommended unless there is a concomitant bacterial infection or strong suspicion of one.

Prevention

The guidelines advise that palivizumab (Synagis) should not be given to otherwise healthy infants with a gestational age of 29 weeks or greater. Palivizumab should be given in the first year of life to infants with hemodynamically significant heart disease or chronic lung disease of prematurity (defined as infants of less than 32 weeks’ gestation who required more than 21% oxygen for at least the first 28 days of life). Infants who qualify for palivizumab at the start of respiratory syncytial virus season should receive a maximum of five monthly doses (15 mg/kg per dose) of palivizumab or until the end of RSV season, whichever comes first. Because of the low risk of RSV hospitalization in the second year of life, palivizumab prophylaxis is not recommended for children in the second year of life, unless the child meets the criteria for chronic lung disease and continues to require supplemental oxygen or is on chronic corticosteroids or diuretic therapy within 6 months of the onset of the second RSV season.

 

 

Reference

Ralston S.L. "Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis." Pediatrics 2014;134:e1474-502).

Dr. Skolnik is associate director of the family medicine residency program at Abington (Pa.) Memorial Hospital and professor of family and community medicine at Temple University in Philadelphia. Dr. Rastogi is a third-year resident in the family medicine residency program at Abington Memorial Hospital.

References

Ralston S.L. “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.” Pediatrics 2014;134:e1474-502).

Author and Disclosure Information

Publications
Topics
Legacy Keywords
Bronchiolitis, infants, American Academy of Pediatrics, guidelines
Sections
Author and Disclosure Information

Author and Disclosure Information

Bronchiolitis is the most common cause of hospitalization among infants during the first 12 months of life. Approximately 100,000 bronchiolitis admissions occur annually in children in the United States, at an estimated cost of $1.73 billion. The American Academy of Pediatrics recently published new guidelines for the diagnosis, management, and prevention of bronchiolitis in children younger than 2 years.

Dr. Neil Skolnik and Dr. Neha Rastogi

Diagnosis

Diagnosis is based on patient history and physical examination. The course and severity of bronchiolitis vary, ranging from mild disease with simple runny nose and cough, to transient apneic events, and on to progressive respiratory distress secondary to airway obstruction. Management of bronchiolitis must be determined in the context of increased risk factors for severe disease, including age less than 12 weeks, history of prematurity, underlying cardiopulmonary disease, and immunodeficiency. Current evidence does not support routine labs or diagnostic imaging as helping with risk assessment. Abnormalities on chest x-ray, which are common in children with bronchiolitis, do reliably predict severity of disease, so chest x-rays are only indicated when another etiology of respiratory distress such as pneumothorax or pneumonia is a concern. Routine virologic testing is not recommended, as it does not appear to aid in guiding the treatment of the child with bronchiolitis.

Management

Randomized trials have not shown any benefit from alpha- or beta-adrenergic agonist administration. Bronchodilators can lessen symptoms scores, but their use does not speed disease resolution or decrease the length of stay or need for hospitalization. A Cochrane analysis concluded that there was no benefit to giving bronchodilators to infants with bronchiolitis. Adverse effects included tachycardia, tremors, and cost, all of which outweigh potential benefits. While previous versions of the AAP guidelines recommended bronchodilators as an option, the 2014 guidelines state, “Clinicians should not administer albuterol (or salbutamol) to infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Strong).” It is noted that there may be some children who have reversible airway obstruction, but it is impossible to tell ahead of time who they are; and due to the variability of the disease, it is even hard to tell in whom the medication is effective. It is acknowledged that children with severe disease were usually excluded from the studies of bronchodilators. Epinephrine should also not be used except potentially as a rescue agent in severe disease.

Nebulized hypertonic saline appears to increase mucociliary clearance. Nebulized 3% saline is safe and effective in improving symptoms of mild to moderate bronchiolitis when measured after 24 hours of use, and it possibly decreases the length of hospital stay in studies where the length of stay exceeded 3 days. The guidelines conclude that hypertonic saline may be helpful to infants who are hospitalized with bronchiolitis, but probably is of very little benefit when administered in an emergency department setting.

Although there is strong evidence of benefit of systemic corticosteroids in asthma and croup, there is no evidence that systemic corticosteroids provide benefit in bronchiolitis. In addition, there is some evidence that corticosteroids may prolong viral shedding. For these reasons, the 2014 guidelines state, “Clinicians should not administer systemic corticosteroids to infants with a diagnosis of bronchiolitis in any setting (Evidence Quality: A; Recommendation Strength: Strong Recommendation).”

Physicians may choose not to give supplemental oxygen if oxyhemoglobin saturation is more than 90%, and also not to use continuous pulse oximetry given that it is prone to errors of measurement. Chest physiotherapy is not recommended. Antibiotics use is not recommended unless there is a concomitant bacterial infection or strong suspicion of one.

Prevention

The guidelines advise that palivizumab (Synagis) should not be given to otherwise healthy infants with a gestational age of 29 weeks or greater. Palivizumab should be given in the first year of life to infants with hemodynamically significant heart disease or chronic lung disease of prematurity (defined as infants of less than 32 weeks’ gestation who required more than 21% oxygen for at least the first 28 days of life). Infants who qualify for palivizumab at the start of respiratory syncytial virus season should receive a maximum of five monthly doses (15 mg/kg per dose) of palivizumab or until the end of RSV season, whichever comes first. Because of the low risk of RSV hospitalization in the second year of life, palivizumab prophylaxis is not recommended for children in the second year of life, unless the child meets the criteria for chronic lung disease and continues to require supplemental oxygen or is on chronic corticosteroids or diuretic therapy within 6 months of the onset of the second RSV season.

 

 

Reference

Ralston S.L. "Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis." Pediatrics 2014;134:e1474-502).

Dr. Skolnik is associate director of the family medicine residency program at Abington (Pa.) Memorial Hospital and professor of family and community medicine at Temple University in Philadelphia. Dr. Rastogi is a third-year resident in the family medicine residency program at Abington Memorial Hospital.

Bronchiolitis is the most common cause of hospitalization among infants during the first 12 months of life. Approximately 100,000 bronchiolitis admissions occur annually in children in the United States, at an estimated cost of $1.73 billion. The American Academy of Pediatrics recently published new guidelines for the diagnosis, management, and prevention of bronchiolitis in children younger than 2 years.

Dr. Neil Skolnik and Dr. Neha Rastogi

Diagnosis

Diagnosis is based on patient history and physical examination. The course and severity of bronchiolitis vary, ranging from mild disease with simple runny nose and cough, to transient apneic events, and on to progressive respiratory distress secondary to airway obstruction. Management of bronchiolitis must be determined in the context of increased risk factors for severe disease, including age less than 12 weeks, history of prematurity, underlying cardiopulmonary disease, and immunodeficiency. Current evidence does not support routine labs or diagnostic imaging as helping with risk assessment. Abnormalities on chest x-ray, which are common in children with bronchiolitis, do reliably predict severity of disease, so chest x-rays are only indicated when another etiology of respiratory distress such as pneumothorax or pneumonia is a concern. Routine virologic testing is not recommended, as it does not appear to aid in guiding the treatment of the child with bronchiolitis.

Management

Randomized trials have not shown any benefit from alpha- or beta-adrenergic agonist administration. Bronchodilators can lessen symptoms scores, but their use does not speed disease resolution or decrease the length of stay or need for hospitalization. A Cochrane analysis concluded that there was no benefit to giving bronchodilators to infants with bronchiolitis. Adverse effects included tachycardia, tremors, and cost, all of which outweigh potential benefits. While previous versions of the AAP guidelines recommended bronchodilators as an option, the 2014 guidelines state, “Clinicians should not administer albuterol (or salbutamol) to infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Strong).” It is noted that there may be some children who have reversible airway obstruction, but it is impossible to tell ahead of time who they are; and due to the variability of the disease, it is even hard to tell in whom the medication is effective. It is acknowledged that children with severe disease were usually excluded from the studies of bronchodilators. Epinephrine should also not be used except potentially as a rescue agent in severe disease.

Nebulized hypertonic saline appears to increase mucociliary clearance. Nebulized 3% saline is safe and effective in improving symptoms of mild to moderate bronchiolitis when measured after 24 hours of use, and it possibly decreases the length of hospital stay in studies where the length of stay exceeded 3 days. The guidelines conclude that hypertonic saline may be helpful to infants who are hospitalized with bronchiolitis, but probably is of very little benefit when administered in an emergency department setting.

Although there is strong evidence of benefit of systemic corticosteroids in asthma and croup, there is no evidence that systemic corticosteroids provide benefit in bronchiolitis. In addition, there is some evidence that corticosteroids may prolong viral shedding. For these reasons, the 2014 guidelines state, “Clinicians should not administer systemic corticosteroids to infants with a diagnosis of bronchiolitis in any setting (Evidence Quality: A; Recommendation Strength: Strong Recommendation).”

Physicians may choose not to give supplemental oxygen if oxyhemoglobin saturation is more than 90%, and also not to use continuous pulse oximetry given that it is prone to errors of measurement. Chest physiotherapy is not recommended. Antibiotics use is not recommended unless there is a concomitant bacterial infection or strong suspicion of one.

Prevention

The guidelines advise that palivizumab (Synagis) should not be given to otherwise healthy infants with a gestational age of 29 weeks or greater. Palivizumab should be given in the first year of life to infants with hemodynamically significant heart disease or chronic lung disease of prematurity (defined as infants of less than 32 weeks’ gestation who required more than 21% oxygen for at least the first 28 days of life). Infants who qualify for palivizumab at the start of respiratory syncytial virus season should receive a maximum of five monthly doses (15 mg/kg per dose) of palivizumab or until the end of RSV season, whichever comes first. Because of the low risk of RSV hospitalization in the second year of life, palivizumab prophylaxis is not recommended for children in the second year of life, unless the child meets the criteria for chronic lung disease and continues to require supplemental oxygen or is on chronic corticosteroids or diuretic therapy within 6 months of the onset of the second RSV season.

 

 

Reference

Ralston S.L. "Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis." Pediatrics 2014;134:e1474-502).

Dr. Skolnik is associate director of the family medicine residency program at Abington (Pa.) Memorial Hospital and professor of family and community medicine at Temple University in Philadelphia. Dr. Rastogi is a third-year resident in the family medicine residency program at Abington Memorial Hospital.

References

Ralston S.L. “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.” Pediatrics 2014;134:e1474-502).

References

Ralston S.L. “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.” Pediatrics 2014;134:e1474-502).

Publications
Publications
Topics
Article Type
Display Headline
CLINICAL GUIDELINES: Primary care bronchiolitis guidelines
Display Headline
CLINICAL GUIDELINES: Primary care bronchiolitis guidelines
Legacy Keywords
Bronchiolitis, infants, American Academy of Pediatrics, guidelines
Legacy Keywords
Bronchiolitis, infants, American Academy of Pediatrics, guidelines
Sections
Article Source

PURLs Copyright

Inside the Article

Topiramate

Article Type
Changed
Display Headline
Topiramate

At Motherisk, we receive increasing numbers of queries from women and clinicians about the use of topiramate during pregnancy, mostly related to its use for migraine or seizures.Topiramate is approved for treatment of seizures and for migraine prevention, and in 2012, the Food and Drug Administration approved the combination of extended-release topiramate with the stimulant phentermine (Qsymia) as a chronic treatment for weight management.

When topiramate was initially approved in 1996, human reproductive data were scarce, but animal data suggested that a high dose of topiramate in rats and rabbits may induce some congenital malformations. Since that time, quite a few studies – but not all – have suggested that topiramate may be associated with an increased risk of oral clefts (cleft lip and cleft palate). Studies that have found an increased risk associated with first trimester exposure to topiramate include the North American AED Pregnancy Registry, which found a rate of 14 cases per 1,000 – more than tenfold greater than the rate in the general population.

For seizures and migraines, the FDA has labeled topiramate a pregnancy category D drug (there is evidence of human fetal risk, but “the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.” ) For Qsymia, however, topiramate is contraindicated in pregnancy and is a pregnancy category X, because its use “can cause fetal harm and weight loss offers no potential benefit to a pregnant woman,” the labeling states.

Based on arecent analysis of six controlled studies in the literature of more than 3,000 pregnancies exposed during the first trimester, we determinedthat the risk of oral clefts associated with first trimester exposure was increased by sixfold over controls. To put this into context, in the general population, oral clefts occur in less than 1% (0.07%), whereas in the studies, the rate was 0.36%, about a fivefold increase.

Until the approval of the weight loss indication, women of reproductive age with epilepsy or migraines prescribed topiramate were a relatively small group. But because obesity is so common, we are now in a situation where a drug that is likely a human teratogen, based on strong evidence, will be used by far more women of childbearing age, and an increase in unintended pregnancies exposed to the drug probably will occur. In phase III clinical trials of Qsymia, quite a few women got pregnant, which is not surprising since women who are obese may have more difficulty knowing they are pregnant, for hormonal and other reasons.

Clinicians and women who take the drug for weight loss need to be aware of this risk. It is important to counsel women of childbearing age who are on this medication about the need for contraception during treatment, and to have a pregnancy test before treatment, and every month during treatment. An important factor to keep in mind is that the maximum topiramate dose for weight loss is 92 mg a day, while the typical epilepsy dose is 200-400 mg a day, and for migraines, is 100 mg a day. It may turn out that the same risk may not be evident with the lower dose.

As the labeling states, women who become pregnant while on this drug should stop taking it immediately, and clinicians should counsel them about the possible risks to the fetus. Health care providers and patients should report pregnancies exposed to Qsymia to the Qsymia Pregnancy Surveillance Program, which is monitoring maternal-fetal outcomes of exposed pregnancies, at 888-998-4887, or the FDA’s MedWatch program at 800-332-1088.

Dr. Koren is professor of pediatrics, pharmacology, pharmacy, medicine, and medical genetics at the University of Toronto. He heads the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation at the Hospital for Sick Children, Toronto, where he is director of the Motherisk Program. He was a consultant to Vivus, the manufacturer of Qsymia. E-mail him at [email protected].

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
topiramate, Qsymia, reproductive, safety, oral, clefts, teratogen, weight, loss, AED, pregnancy, registry
Sections
Author and Disclosure Information

Author and Disclosure Information

At Motherisk, we receive increasing numbers of queries from women and clinicians about the use of topiramate during pregnancy, mostly related to its use for migraine or seizures.Topiramate is approved for treatment of seizures and for migraine prevention, and in 2012, the Food and Drug Administration approved the combination of extended-release topiramate with the stimulant phentermine (Qsymia) as a chronic treatment for weight management.

When topiramate was initially approved in 1996, human reproductive data were scarce, but animal data suggested that a high dose of topiramate in rats and rabbits may induce some congenital malformations. Since that time, quite a few studies – but not all – have suggested that topiramate may be associated with an increased risk of oral clefts (cleft lip and cleft palate). Studies that have found an increased risk associated with first trimester exposure to topiramate include the North American AED Pregnancy Registry, which found a rate of 14 cases per 1,000 – more than tenfold greater than the rate in the general population.

For seizures and migraines, the FDA has labeled topiramate a pregnancy category D drug (there is evidence of human fetal risk, but “the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.” ) For Qsymia, however, topiramate is contraindicated in pregnancy and is a pregnancy category X, because its use “can cause fetal harm and weight loss offers no potential benefit to a pregnant woman,” the labeling states.

Based on arecent analysis of six controlled studies in the literature of more than 3,000 pregnancies exposed during the first trimester, we determinedthat the risk of oral clefts associated with first trimester exposure was increased by sixfold over controls. To put this into context, in the general population, oral clefts occur in less than 1% (0.07%), whereas in the studies, the rate was 0.36%, about a fivefold increase.

Until the approval of the weight loss indication, women of reproductive age with epilepsy or migraines prescribed topiramate were a relatively small group. But because obesity is so common, we are now in a situation where a drug that is likely a human teratogen, based on strong evidence, will be used by far more women of childbearing age, and an increase in unintended pregnancies exposed to the drug probably will occur. In phase III clinical trials of Qsymia, quite a few women got pregnant, which is not surprising since women who are obese may have more difficulty knowing they are pregnant, for hormonal and other reasons.

Clinicians and women who take the drug for weight loss need to be aware of this risk. It is important to counsel women of childbearing age who are on this medication about the need for contraception during treatment, and to have a pregnancy test before treatment, and every month during treatment. An important factor to keep in mind is that the maximum topiramate dose for weight loss is 92 mg a day, while the typical epilepsy dose is 200-400 mg a day, and for migraines, is 100 mg a day. It may turn out that the same risk may not be evident with the lower dose.

As the labeling states, women who become pregnant while on this drug should stop taking it immediately, and clinicians should counsel them about the possible risks to the fetus. Health care providers and patients should report pregnancies exposed to Qsymia to the Qsymia Pregnancy Surveillance Program, which is monitoring maternal-fetal outcomes of exposed pregnancies, at 888-998-4887, or the FDA’s MedWatch program at 800-332-1088.

Dr. Koren is professor of pediatrics, pharmacology, pharmacy, medicine, and medical genetics at the University of Toronto. He heads the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation at the Hospital for Sick Children, Toronto, where he is director of the Motherisk Program. He was a consultant to Vivus, the manufacturer of Qsymia. E-mail him at [email protected].

At Motherisk, we receive increasing numbers of queries from women and clinicians about the use of topiramate during pregnancy, mostly related to its use for migraine or seizures.Topiramate is approved for treatment of seizures and for migraine prevention, and in 2012, the Food and Drug Administration approved the combination of extended-release topiramate with the stimulant phentermine (Qsymia) as a chronic treatment for weight management.

When topiramate was initially approved in 1996, human reproductive data were scarce, but animal data suggested that a high dose of topiramate in rats and rabbits may induce some congenital malformations. Since that time, quite a few studies – but not all – have suggested that topiramate may be associated with an increased risk of oral clefts (cleft lip and cleft palate). Studies that have found an increased risk associated with first trimester exposure to topiramate include the North American AED Pregnancy Registry, which found a rate of 14 cases per 1,000 – more than tenfold greater than the rate in the general population.

For seizures and migraines, the FDA has labeled topiramate a pregnancy category D drug (there is evidence of human fetal risk, but “the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.” ) For Qsymia, however, topiramate is contraindicated in pregnancy and is a pregnancy category X, because its use “can cause fetal harm and weight loss offers no potential benefit to a pregnant woman,” the labeling states.

Based on arecent analysis of six controlled studies in the literature of more than 3,000 pregnancies exposed during the first trimester, we determinedthat the risk of oral clefts associated with first trimester exposure was increased by sixfold over controls. To put this into context, in the general population, oral clefts occur in less than 1% (0.07%), whereas in the studies, the rate was 0.36%, about a fivefold increase.

Until the approval of the weight loss indication, women of reproductive age with epilepsy or migraines prescribed topiramate were a relatively small group. But because obesity is so common, we are now in a situation where a drug that is likely a human teratogen, based on strong evidence, will be used by far more women of childbearing age, and an increase in unintended pregnancies exposed to the drug probably will occur. In phase III clinical trials of Qsymia, quite a few women got pregnant, which is not surprising since women who are obese may have more difficulty knowing they are pregnant, for hormonal and other reasons.

Clinicians and women who take the drug for weight loss need to be aware of this risk. It is important to counsel women of childbearing age who are on this medication about the need for contraception during treatment, and to have a pregnancy test before treatment, and every month during treatment. An important factor to keep in mind is that the maximum topiramate dose for weight loss is 92 mg a day, while the typical epilepsy dose is 200-400 mg a day, and for migraines, is 100 mg a day. It may turn out that the same risk may not be evident with the lower dose.

As the labeling states, women who become pregnant while on this drug should stop taking it immediately, and clinicians should counsel them about the possible risks to the fetus. Health care providers and patients should report pregnancies exposed to Qsymia to the Qsymia Pregnancy Surveillance Program, which is monitoring maternal-fetal outcomes of exposed pregnancies, at 888-998-4887, or the FDA’s MedWatch program at 800-332-1088.

Dr. Koren is professor of pediatrics, pharmacology, pharmacy, medicine, and medical genetics at the University of Toronto. He heads the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation at the Hospital for Sick Children, Toronto, where he is director of the Motherisk Program. He was a consultant to Vivus, the manufacturer of Qsymia. E-mail him at [email protected].

References

References

Publications
Publications
Topics
Article Type
Display Headline
Topiramate
Display Headline
Topiramate
Legacy Keywords
topiramate, Qsymia, reproductive, safety, oral, clefts, teratogen, weight, loss, AED, pregnancy, registry
Legacy Keywords
topiramate, Qsymia, reproductive, safety, oral, clefts, teratogen, weight, loss, AED, pregnancy, registry
Sections
Article Source

PURLs Copyright

Inside the Article

The Complexities of Competency

Article Type
Changed
Display Headline
The Complexities of Competency
Questions have arisen as to when a clinician is “fully competent” to see patients—but what does that mean, and how do we measure it?

Rarely do I post online as a knee-jerk reaction! But recently, a topic hit me right in the middle of the forehead. I received an email from a colleague who asked:

“Is there any study looking at how long a PA or NP needs after completing his/her training to be fully competent? I’m at a hospital board meeting and one member is suggesting ‘midlevels’ need three more years of training, at the expense of the institution hiring them.”

I must admit that I was at a loss as to how to respond! (Not least because I dislike the term midlevel.) Lately, competency has been a hot topic as hospitals and large health care organizations hire more new graduates and want to know how long it will take for them to get up to speed within the institution. Competence is thus defined as how long it takes these PAs/NPs to become fully functional in a particular setting. It’s a narrow, specific question rather than a broad, philosophical one—but it begs the competency question, does it not?

Let’s start with the definition of competency. I had to laugh when I consulted Merriam-Webster, which says competency is “the quality or state of being functionally adequate.” Now, that is what I strive to be … “adequate”!  

I prefer Norman’s definition of professional competence: “The habitual and judicious use of communication, knowledge, technical skills, clinical reasoning, emotions, values, and reflection in daily practice for the benefit of the individual and community being served. Competence builds on a foundation of basic clinical skills, scientific knowledge, and moral development.”1

He goes on to say that competence has multiple functions: cognitive (using acquired knowledge to solve real-life problems); integrative (using biomedical and psychosocial data in clinical reasoning); relational (communicating effectively with patients and colleagues); and affective/moral (the willingness, patience, and emotional awareness to use these skills judiciously and humanely). I was particularly struck by a final comment that competence is “developmental, impermanent, and context-dependent.”1 Competence is certainly developmental in the context of lifelong learning. If it is indeed impermanent (temporary, transient, transitory, passing, fleeting), then it must be evaluated frequently. There is no argument that it is context-dependent, whether by level of care, specialty knowledge required, or institution.

Clearly, competence is complex. While the PA and NP professions have developed and published clinical competencies in the past decade (which mirror and parallel those of our physician colleagues), how do we actually demonstrate them?

Continue for competency definitions >>

 

 

Patricia Benner developed one of the best-known competency definitions in 1982 with her Novice to Expert model, which applied the Dreyfus Model of Skill Acquisition to nursing. It has been widely used as a tool to determine “expertise.”2,3 Her model describes the five levels of expertise as
Novice: A beginner with little to no experience. Novices face the inability to use discretionary judgment and require significant supervision.
Advanced beginner: Able to demonstrate marginally acceptable performance based on some real-life experience.
Competent: Has usually been on the job for two to three years. At this level, the clinician has a sense of mastery and the ability to cope with and manage many aspects of patient care.
Proficient: Able to grasp clinical solutions quicker and able to hone in on accurate regions of the problem faster.
Expert: No longer relies on analytics to connect to understanding of the problem but has an intuitive grasp and is able to zero in on all aspects of the problem at hand without any wasteful or unfruitful possibilities.3

Benner maintains that knowledge accrues over time in clinical practice and is developed through dialogue in relationship and situational contexts.4 Of note, clinical experience is not the mere passage of time or longevity within a clinical experience but rather the actual level of clinical interaction. The clinician, therefore, may move forward or backward, depending on the situation.

In 2011, Chuck defined six levels of competency, postulating that for each we find ways to scale the learning curve. It is where we are on the curve that determines our competence in a skill set. His six levels include
Naïve/Newcomer: Exhibits little observable knowledge, skill, or sincere interest
Intermediate: Has received minimal but not sufficient training to exhibit a core set of knowledge, skills, or ­interest
Proficient: Has completed sufficient training (usually through a set of required classes) to reliably reproduce a core set of knowledge and skills, but requires further training when confronted with situations in which it needs to be applied
Confident: Has above-average knowledge and skills and demonstrates appropriate confidence in adapting to new situations that challenge those skills
Master: Demonstrates consistent excellence in knowledge and skills and can appropriately seek affirmation and criticism to independently develop additional skills
Expert: Has received external validation of superior quality knowledge and skills and is considered an innovator, leader, or authority in a specific area.5

In the Chuck model, levels 1 and 2 would be prematriculants and students. You can see variations of this learning curve in different situations, whether it is a new clinician in the emergency department (ED) or an experienced clinician moving to a new practice.

So when is a clinician (specifically, a PA or NP) fully competent to see patients? This question is undoubtedly being asked more than we realize, and both professions should develop a serious answer to it. Are we doing enough research to make an objective argument in response? No matter how we answer, I think it is important to note that our respective professions have excellent patient care outcomes, even when taking into account the particular clinician level (novice through expert).

This is a challenging topic because what we do requires factual knowledge and the consistent, appropriate application of that knowledge. We know how to measure factual knowledge, more or less, but assuredly we don’t know how to measure the latter (possibly the more important part). In my opinion, we need a pragmatic approach to determine whether a clinician is competent and continues to be so.

One method is to do what is known as a 360 survey. Here’s how it might work: All coworkers of a particular clinician would be surveyed on the perceived elements of clinical competence, including knowledge, application of knowledge, efficiency, ability to make decisions, and attitude toward patients. Every person in the department—say, the ED—could anonymously complete the survey. (This would include nurses, techs, other PAs/NPs, housekeeping, on-call members of the medical staff—literally everybody, although not all of them will be capable of making some of these determinations.) Then the ED director would let the clinician review and discuss the feedback. Everyone in the department would know he or she would be similarly evaluated.6

This is the most brutal, yet fair and efficient, way to assess competency in its broadest sense. Will all opinions be factually substantiated? No! But what better technique do we have, at least for now?

But wait! Perhaps competence is not the end game. Perhaps competence is really a minimum standard. Competence (albeit novice) is measured by completion of the PA or NP curricula (meeting the course objectives) and passage of board/licensure exams, just as, essentially, physician competence is.

Most, if not all, would agree that mastery is achieved by the acquisition of knowledge coupled with sound practice and experience. Mastery or expertise, some say, is what we should focus on, the achievement of which is quite individual. All clinicians can move toward mastery, but not all will actually achieve it. Therefore, how can we mandate a minimum standard, beyond competence, for PAs and NPs but not for other providers?

So, after all the rhetorical ranting about when a PA or NP becomes fully competent, the answer is … It depends! There are too many moving parts. I would suggest that competency is the starting point and mastery (expertise) is a journey.

What do you think? Share your thoughts with me via [email protected].

REFERENCES
1. Norman GR. Defining competence: a methodological review. In: Neufeld VR, Norman GR, eds. Assessing Clinical Competence. New York, NY: Springer; 1985:15-35.

2. Gentile DL. Applying the novice-to-expert model to infusion nursing. J Infus Nurs. 2012;35(2):101-107.

3. Benner P. From novice to expert. Am J Nurs. 1982;82(3):402-407.

4. Brykczynski KA. Patricia Benner: caring, clinical wisdom, and ethics in nursing practice. In: Alligood MR, ed. Nursing Theorists and Their Work. 8th ed. St Louis, MO: Elsevier. 2014; 120-146.

5. Chuck E. The competency manifesto: part 3. The Student Doctor Network. www.student doctor.net/2011/04/the-competency-mani festo-part-3. Accessed November 11, 2014.

6. Lepsinger R, Luca AD. The Art and Science of 360-Degree Feedback. 2nd ed. San Francisco, CA: Jossey-Bass; 2009. 

References

Article PDF
Author and Disclosure Information

Randy D. Danielsen PhD, PA-C, DFAAPA

Issue
Clinician Reviews - 24(12)
Publications
Topics
Page Number
6-8
Legacy Keywords
competence, competency, novice, expert, experience, knowledge, training, education, Patricia Benner, skill set, feedback, evaluation, assessment, patient care, standard
Sections
Author and Disclosure Information

Randy D. Danielsen PhD, PA-C, DFAAPA

Author and Disclosure Information

Randy D. Danielsen PhD, PA-C, DFAAPA

Article PDF
Article PDF
Questions have arisen as to when a clinician is “fully competent” to see patients—but what does that mean, and how do we measure it?
Questions have arisen as to when a clinician is “fully competent” to see patients—but what does that mean, and how do we measure it?

Rarely do I post online as a knee-jerk reaction! But recently, a topic hit me right in the middle of the forehead. I received an email from a colleague who asked:

“Is there any study looking at how long a PA or NP needs after completing his/her training to be fully competent? I’m at a hospital board meeting and one member is suggesting ‘midlevels’ need three more years of training, at the expense of the institution hiring them.”

I must admit that I was at a loss as to how to respond! (Not least because I dislike the term midlevel.) Lately, competency has been a hot topic as hospitals and large health care organizations hire more new graduates and want to know how long it will take for them to get up to speed within the institution. Competence is thus defined as how long it takes these PAs/NPs to become fully functional in a particular setting. It’s a narrow, specific question rather than a broad, philosophical one—but it begs the competency question, does it not?

Let’s start with the definition of competency. I had to laugh when I consulted Merriam-Webster, which says competency is “the quality or state of being functionally adequate.” Now, that is what I strive to be … “adequate”!  

I prefer Norman’s definition of professional competence: “The habitual and judicious use of communication, knowledge, technical skills, clinical reasoning, emotions, values, and reflection in daily practice for the benefit of the individual and community being served. Competence builds on a foundation of basic clinical skills, scientific knowledge, and moral development.”1

He goes on to say that competence has multiple functions: cognitive (using acquired knowledge to solve real-life problems); integrative (using biomedical and psychosocial data in clinical reasoning); relational (communicating effectively with patients and colleagues); and affective/moral (the willingness, patience, and emotional awareness to use these skills judiciously and humanely). I was particularly struck by a final comment that competence is “developmental, impermanent, and context-dependent.”1 Competence is certainly developmental in the context of lifelong learning. If it is indeed impermanent (temporary, transient, transitory, passing, fleeting), then it must be evaluated frequently. There is no argument that it is context-dependent, whether by level of care, specialty knowledge required, or institution.

Clearly, competence is complex. While the PA and NP professions have developed and published clinical competencies in the past decade (which mirror and parallel those of our physician colleagues), how do we actually demonstrate them?

Continue for competency definitions >>

 

 

Patricia Benner developed one of the best-known competency definitions in 1982 with her Novice to Expert model, which applied the Dreyfus Model of Skill Acquisition to nursing. It has been widely used as a tool to determine “expertise.”2,3 Her model describes the five levels of expertise as
Novice: A beginner with little to no experience. Novices face the inability to use discretionary judgment and require significant supervision.
Advanced beginner: Able to demonstrate marginally acceptable performance based on some real-life experience.
Competent: Has usually been on the job for two to three years. At this level, the clinician has a sense of mastery and the ability to cope with and manage many aspects of patient care.
Proficient: Able to grasp clinical solutions quicker and able to hone in on accurate regions of the problem faster.
Expert: No longer relies on analytics to connect to understanding of the problem but has an intuitive grasp and is able to zero in on all aspects of the problem at hand without any wasteful or unfruitful possibilities.3

Benner maintains that knowledge accrues over time in clinical practice and is developed through dialogue in relationship and situational contexts.4 Of note, clinical experience is not the mere passage of time or longevity within a clinical experience but rather the actual level of clinical interaction. The clinician, therefore, may move forward or backward, depending on the situation.

In 2011, Chuck defined six levels of competency, postulating that for each we find ways to scale the learning curve. It is where we are on the curve that determines our competence in a skill set. His six levels include
Naïve/Newcomer: Exhibits little observable knowledge, skill, or sincere interest
Intermediate: Has received minimal but not sufficient training to exhibit a core set of knowledge, skills, or ­interest
Proficient: Has completed sufficient training (usually through a set of required classes) to reliably reproduce a core set of knowledge and skills, but requires further training when confronted with situations in which it needs to be applied
Confident: Has above-average knowledge and skills and demonstrates appropriate confidence in adapting to new situations that challenge those skills
Master: Demonstrates consistent excellence in knowledge and skills and can appropriately seek affirmation and criticism to independently develop additional skills
Expert: Has received external validation of superior quality knowledge and skills and is considered an innovator, leader, or authority in a specific area.5

In the Chuck model, levels 1 and 2 would be prematriculants and students. You can see variations of this learning curve in different situations, whether it is a new clinician in the emergency department (ED) or an experienced clinician moving to a new practice.

So when is a clinician (specifically, a PA or NP) fully competent to see patients? This question is undoubtedly being asked more than we realize, and both professions should develop a serious answer to it. Are we doing enough research to make an objective argument in response? No matter how we answer, I think it is important to note that our respective professions have excellent patient care outcomes, even when taking into account the particular clinician level (novice through expert).

This is a challenging topic because what we do requires factual knowledge and the consistent, appropriate application of that knowledge. We know how to measure factual knowledge, more or less, but assuredly we don’t know how to measure the latter (possibly the more important part). In my opinion, we need a pragmatic approach to determine whether a clinician is competent and continues to be so.

One method is to do what is known as a 360 survey. Here’s how it might work: All coworkers of a particular clinician would be surveyed on the perceived elements of clinical competence, including knowledge, application of knowledge, efficiency, ability to make decisions, and attitude toward patients. Every person in the department—say, the ED—could anonymously complete the survey. (This would include nurses, techs, other PAs/NPs, housekeeping, on-call members of the medical staff—literally everybody, although not all of them will be capable of making some of these determinations.) Then the ED director would let the clinician review and discuss the feedback. Everyone in the department would know he or she would be similarly evaluated.6

This is the most brutal, yet fair and efficient, way to assess competency in its broadest sense. Will all opinions be factually substantiated? No! But what better technique do we have, at least for now?

But wait! Perhaps competence is not the end game. Perhaps competence is really a minimum standard. Competence (albeit novice) is measured by completion of the PA or NP curricula (meeting the course objectives) and passage of board/licensure exams, just as, essentially, physician competence is.

Most, if not all, would agree that mastery is achieved by the acquisition of knowledge coupled with sound practice and experience. Mastery or expertise, some say, is what we should focus on, the achievement of which is quite individual. All clinicians can move toward mastery, but not all will actually achieve it. Therefore, how can we mandate a minimum standard, beyond competence, for PAs and NPs but not for other providers?

So, after all the rhetorical ranting about when a PA or NP becomes fully competent, the answer is … It depends! There are too many moving parts. I would suggest that competency is the starting point and mastery (expertise) is a journey.

What do you think? Share your thoughts with me via [email protected].

REFERENCES
1. Norman GR. Defining competence: a methodological review. In: Neufeld VR, Norman GR, eds. Assessing Clinical Competence. New York, NY: Springer; 1985:15-35.

2. Gentile DL. Applying the novice-to-expert model to infusion nursing. J Infus Nurs. 2012;35(2):101-107.

3. Benner P. From novice to expert. Am J Nurs. 1982;82(3):402-407.

4. Brykczynski KA. Patricia Benner: caring, clinical wisdom, and ethics in nursing practice. In: Alligood MR, ed. Nursing Theorists and Their Work. 8th ed. St Louis, MO: Elsevier. 2014; 120-146.

5. Chuck E. The competency manifesto: part 3. The Student Doctor Network. www.student doctor.net/2011/04/the-competency-mani festo-part-3. Accessed November 11, 2014.

6. Lepsinger R, Luca AD. The Art and Science of 360-Degree Feedback. 2nd ed. San Francisco, CA: Jossey-Bass; 2009. 

Rarely do I post online as a knee-jerk reaction! But recently, a topic hit me right in the middle of the forehead. I received an email from a colleague who asked:

“Is there any study looking at how long a PA or NP needs after completing his/her training to be fully competent? I’m at a hospital board meeting and one member is suggesting ‘midlevels’ need three more years of training, at the expense of the institution hiring them.”

I must admit that I was at a loss as to how to respond! (Not least because I dislike the term midlevel.) Lately, competency has been a hot topic as hospitals and large health care organizations hire more new graduates and want to know how long it will take for them to get up to speed within the institution. Competence is thus defined as how long it takes these PAs/NPs to become fully functional in a particular setting. It’s a narrow, specific question rather than a broad, philosophical one—but it begs the competency question, does it not?

Let’s start with the definition of competency. I had to laugh when I consulted Merriam-Webster, which says competency is “the quality or state of being functionally adequate.” Now, that is what I strive to be … “adequate”!  

I prefer Norman’s definition of professional competence: “The habitual and judicious use of communication, knowledge, technical skills, clinical reasoning, emotions, values, and reflection in daily practice for the benefit of the individual and community being served. Competence builds on a foundation of basic clinical skills, scientific knowledge, and moral development.”1

He goes on to say that competence has multiple functions: cognitive (using acquired knowledge to solve real-life problems); integrative (using biomedical and psychosocial data in clinical reasoning); relational (communicating effectively with patients and colleagues); and affective/moral (the willingness, patience, and emotional awareness to use these skills judiciously and humanely). I was particularly struck by a final comment that competence is “developmental, impermanent, and context-dependent.”1 Competence is certainly developmental in the context of lifelong learning. If it is indeed impermanent (temporary, transient, transitory, passing, fleeting), then it must be evaluated frequently. There is no argument that it is context-dependent, whether by level of care, specialty knowledge required, or institution.

Clearly, competence is complex. While the PA and NP professions have developed and published clinical competencies in the past decade (which mirror and parallel those of our physician colleagues), how do we actually demonstrate them?

Continue for competency definitions >>

 

 

Patricia Benner developed one of the best-known competency definitions in 1982 with her Novice to Expert model, which applied the Dreyfus Model of Skill Acquisition to nursing. It has been widely used as a tool to determine “expertise.”2,3 Her model describes the five levels of expertise as
Novice: A beginner with little to no experience. Novices face the inability to use discretionary judgment and require significant supervision.
Advanced beginner: Able to demonstrate marginally acceptable performance based on some real-life experience.
Competent: Has usually been on the job for two to three years. At this level, the clinician has a sense of mastery and the ability to cope with and manage many aspects of patient care.
Proficient: Able to grasp clinical solutions quicker and able to hone in on accurate regions of the problem faster.
Expert: No longer relies on analytics to connect to understanding of the problem but has an intuitive grasp and is able to zero in on all aspects of the problem at hand without any wasteful or unfruitful possibilities.3

Benner maintains that knowledge accrues over time in clinical practice and is developed through dialogue in relationship and situational contexts.4 Of note, clinical experience is not the mere passage of time or longevity within a clinical experience but rather the actual level of clinical interaction. The clinician, therefore, may move forward or backward, depending on the situation.

In 2011, Chuck defined six levels of competency, postulating that for each we find ways to scale the learning curve. It is where we are on the curve that determines our competence in a skill set. His six levels include
Naïve/Newcomer: Exhibits little observable knowledge, skill, or sincere interest
Intermediate: Has received minimal but not sufficient training to exhibit a core set of knowledge, skills, or ­interest
Proficient: Has completed sufficient training (usually through a set of required classes) to reliably reproduce a core set of knowledge and skills, but requires further training when confronted with situations in which it needs to be applied
Confident: Has above-average knowledge and skills and demonstrates appropriate confidence in adapting to new situations that challenge those skills
Master: Demonstrates consistent excellence in knowledge and skills and can appropriately seek affirmation and criticism to independently develop additional skills
Expert: Has received external validation of superior quality knowledge and skills and is considered an innovator, leader, or authority in a specific area.5

In the Chuck model, levels 1 and 2 would be prematriculants and students. You can see variations of this learning curve in different situations, whether it is a new clinician in the emergency department (ED) or an experienced clinician moving to a new practice.

So when is a clinician (specifically, a PA or NP) fully competent to see patients? This question is undoubtedly being asked more than we realize, and both professions should develop a serious answer to it. Are we doing enough research to make an objective argument in response? No matter how we answer, I think it is important to note that our respective professions have excellent patient care outcomes, even when taking into account the particular clinician level (novice through expert).

This is a challenging topic because what we do requires factual knowledge and the consistent, appropriate application of that knowledge. We know how to measure factual knowledge, more or less, but assuredly we don’t know how to measure the latter (possibly the more important part). In my opinion, we need a pragmatic approach to determine whether a clinician is competent and continues to be so.

One method is to do what is known as a 360 survey. Here’s how it might work: All coworkers of a particular clinician would be surveyed on the perceived elements of clinical competence, including knowledge, application of knowledge, efficiency, ability to make decisions, and attitude toward patients. Every person in the department—say, the ED—could anonymously complete the survey. (This would include nurses, techs, other PAs/NPs, housekeeping, on-call members of the medical staff—literally everybody, although not all of them will be capable of making some of these determinations.) Then the ED director would let the clinician review and discuss the feedback. Everyone in the department would know he or she would be similarly evaluated.6

This is the most brutal, yet fair and efficient, way to assess competency in its broadest sense. Will all opinions be factually substantiated? No! But what better technique do we have, at least for now?

But wait! Perhaps competence is not the end game. Perhaps competence is really a minimum standard. Competence (albeit novice) is measured by completion of the PA or NP curricula (meeting the course objectives) and passage of board/licensure exams, just as, essentially, physician competence is.

Most, if not all, would agree that mastery is achieved by the acquisition of knowledge coupled with sound practice and experience. Mastery or expertise, some say, is what we should focus on, the achievement of which is quite individual. All clinicians can move toward mastery, but not all will actually achieve it. Therefore, how can we mandate a minimum standard, beyond competence, for PAs and NPs but not for other providers?

So, after all the rhetorical ranting about when a PA or NP becomes fully competent, the answer is … It depends! There are too many moving parts. I would suggest that competency is the starting point and mastery (expertise) is a journey.

What do you think? Share your thoughts with me via [email protected].

REFERENCES
1. Norman GR. Defining competence: a methodological review. In: Neufeld VR, Norman GR, eds. Assessing Clinical Competence. New York, NY: Springer; 1985:15-35.

2. Gentile DL. Applying the novice-to-expert model to infusion nursing. J Infus Nurs. 2012;35(2):101-107.

3. Benner P. From novice to expert. Am J Nurs. 1982;82(3):402-407.

4. Brykczynski KA. Patricia Benner: caring, clinical wisdom, and ethics in nursing practice. In: Alligood MR, ed. Nursing Theorists and Their Work. 8th ed. St Louis, MO: Elsevier. 2014; 120-146.

5. Chuck E. The competency manifesto: part 3. The Student Doctor Network. www.student doctor.net/2011/04/the-competency-mani festo-part-3. Accessed November 11, 2014.

6. Lepsinger R, Luca AD. The Art and Science of 360-Degree Feedback. 2nd ed. San Francisco, CA: Jossey-Bass; 2009. 

References

References

Issue
Clinician Reviews - 24(12)
Issue
Clinician Reviews - 24(12)
Page Number
6-8
Page Number
6-8
Publications
Publications
Topics
Article Type
Display Headline
The Complexities of Competency
Display Headline
The Complexities of Competency
Legacy Keywords
competence, competency, novice, expert, experience, knowledge, training, education, Patricia Benner, skill set, feedback, evaluation, assessment, patient care, standard
Legacy Keywords
competence, competency, novice, expert, experience, knowledge, training, education, Patricia Benner, skill set, feedback, evaluation, assessment, patient care, standard
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media